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List of abbreviations 
 
 
°C    degrees Celsius 
95% CI   95% confidence interval 
µg    microgram 
ACTH    adenocorticotropic  hormone   
ALP    alkaline phosphatase 
ALT    alanine aminotransferase  
AST    aspartate aminotransferase 
CETP     cholesteryl ester transfer protein 
dL    deciliter 
EDTA    ethylenediaminetetraacetic acid 
GGT    gamma-glutamyl transferase 
HDL    high density lipoprotein 
IDL    intermediate density lipoprotein 
L    liter 
LCAT     lecithin-cholesterol acyl transferase 
LDL    low density lipoprotein 
LPL    lipoprotein lipase 
mg    milligram  
min    minutes 
mL    milliliter 
NAFLD   non-alcoholic fatty liver disease 
NEFA     nonesterified fatty acid 
p    p value 
PLN    protein-loosing nephropathy 
rpm    revolutions per minute 
VLDL    very low density lipoprotein 
x g    centrifugal force, expressed as x gravity 
 
Table of contents 
 II 
Table of contents 
 
I Introduction         1 
 
II Literature review        3 
1.  Lipids         3 
2.  Lipoproteins        4 
3.  Apolipoproteins       6 
3.1.  Apolipoprotein C-II       8 
4.  Plasma lipid enzymes       8 
4.1.  Lipoprotein lipase       8 
4.2.  Hepatic triglyceride lipase      9 
4.3.  Lecithin-cholesterol acyl transferase (LCAT)   10 
4.4.  Cholesteryl ester transfer protein (CETP)    10 
5.  Lipid metabolism       10 
5.1.  Exogenous pathway       11 
5.2.  Endogenous pathway       12 
6.  Disorders of lipid metabolism     14 
6.1.  Definitions        14 
6.2.  Laboratory evaluation of lipid disorders    15 
6.2.1.  Serum turbidity       15 
6.2.2.  Refrigeration test       17 
6.2.3.  Methods for quantification and characterization of lipids in blood 19 
6.3.  Causes of hyperlipidemia in dogs     19 
6.3.1.  Secondary causes of hyperlipidemia in dogs    19 
6.3.1.1. Endocrine diseases       19 
6.3.1.2. Pancreatitis        20 
6.3.1.3. Obesity        21 
6.3.1.4. Protein losing nephropathy (PLN)     21 
6.3.1.5. Cholestasis        22 
6.3.1.6. Other causes        22 
6.3.2.  Primary causes of hyperlipidemia in dogs    23 
Table of contents 
 III 
6.4.  Clinical signs and complications of hyperlipidemia   24 
6.4.1.  Pancreatitis        24 
6.4.2.  Atherosclerosis       26 
6.4.3.  Insulin resistance and diabetes mellitus    27 
6.4.4.  Liver disease        28 
6.4.5.  Ocular disease        29 
6.4.6.  Other possible complications of hyperlipidemia in dogs  30 
6.5.  Treatment of hyperlipidemia in dogs    30 
6.5.1.  Dietary management       31 
6.5.2.  Medical management       31 
 
III Publications         34 
1.  Investigation of hypertriglyceridemia in healthy Miniature  34 
Schnauzers  
1.1.  Abstract        35 
1.2.  Key words        35 
1.3.  Introduction        36 
1.4.  Materials and Methods      37 
1.5.  Results        40 
1.6.  Discussion        49 
1.7.  Footnotes        54 
1.8.  References        55 
2.  Serum liver enzyme activities in healthy Miniature Schnauzers 57 
with and without hypertriglyceridemia 
2.1.  Abstract        58 
2.2.  Abbreviations        58 
2.3.  Introduction        59 
2.4.  Materials and Methods      60 
2.5.  Results        62 
2.6.  Discussion        69 
2.7.  Footnotes        73 
2.8.  References        74 
 
Table of contents 
 IV 
IV Discussion         77 
 
V Summary         84 
 
VI Zusammenfassung        86 
 
VII References         88 
 
VIII Legends for tables and figures      105 
 
IX Acknowledgements        106 
 
 
 
Introduction 
 1 
I    Introduction 
Hypertriglyceridemia, which refers to abnormally increased serum triglyceride 
concentrations, is a relatively common clinicopathologic finding in dogs. Idiopathic 
hypertriglyceridemia appears to be associated with specific breeds, most commonly 
the Miniature Schnauzer (ROGERS et al., 1975a; WHITNEY, 1992; FORD, 1993; 
WHITNEY et al., 1993; BAUER, 2004). Idiopathic hypertriglyceridemia has been 
reported in Miniature Schnauzers in the United States, but has not been documented 
in this breed elsewhere (ROGERS et al., 1975a; WHITNEY, 1992; FORD, 1993; 
WHITNEY et al., 1993). The cause of hypertriglyceridemia in Miniature Schnauzers 
remains unclear, but possible mechanisms include increased production of VLDL and 
chylomicrons, decreased clearance of VLDL and chylomicrons, or both. The fact that 
hypertriglyceridemia is more prevalent in a specific breed suggests a possible 
hereditary mechanism (ROGERS et al., 1975a; FORD, 1993; WHITNEY et al., 
1993). Although it is generally accepted that idiopathic hypertriglyceridemia is a 
common disorder in Miniature Schnauzers in the United States, and despite the fact 
that it can potentially be associated with serious diseases (e.g., pancreatitis), it has 
received limited attention. The assumption that Miniature Schnauzers have a high 
incidence of primary hypertriglyceridemia compared to other breeds is largely 
anecdotal or based on small case series (ROGERS et al., 1975a; WHITNEY et al., 
1993). Studies investigating the prevalence and clinical implications of this condition 
in large populations of Miniature Schnauzers are lacking. Also, the effects of age, sex, 
and reproductive status on serum triglyceride concentrations have not been 
sufficiently studied in Miniature Schnauzers.  
 
In human beings, hypertriglyceridemia has been associated with the development of 
fatty liver and a condition known as non-alcoholic fatty liver disease (NAFLD) 
(ASSY et al., 2000; ANGULO, 2002; NEUSCHWANDER-TETRI & CALDWELL, 
2003; DE BRUIN et al., 2004; BROUWERS et al., 2007). The prevalence of fatty 
liver in patients with hyperlipidemia, including both hypertriglyceridemia and 
hypercholesterolemia, has been reported to be about 50% (ASSY et al., 2000; 
BROUWERS et al., 2007). Most human patients with NAFLD remain asymptomatic 
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for long periods and many of these patients have only abnormally high serum hepatic 
enzyme activities as the initial manifestation of NAFLD (ASSY et al., 2000; 
ANGULO, 2002; NEUSCHWANDER-TETRI & CALDWELL, 2003). Liver enzyme 
activities are usually only mildly increased (i.e., < 2 times the upper reference limit), 
with high concentrations typically being identified during routine screening 
(ANGULO, 2002; NEUSCHWANDER-TETRI & CALDWELL, 2003). Studies 
investigating a possible association between hypertriglyceridemia, high serum liver 
enzyme activities, and liver disease in dogs have not been described.  
 
The present study consisted of two parts. The hypothesis of the first part of this study 
was that hypertriglyceridemia is prevalent among Miniature Schnauzers that appear to 
be healthy. To prove or disprove this hypothesis, the aim of this first part of the study 
was to determine the prevalence of hypertriglyceridemia in a large population of 
healthy Miniature Schnauzers and to further characterize this condition in this breed.  
 
The hypothesis of the second part of the present study was that hypertriglyceridemia 
in overtly healthy Miniature Schnauzers is associated with increased serum liver 
enzyme activities. To prove or disprove this hypothesis the goal of the second part of 
this study was to measure serum hepatic enzyme activities in healthy 
hypertriglyceridemic Miniature Schnauzers.  
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II    Literature review 
1.    Lipids 
Lipids are water-insoluble organic compounds, which are present in almost every 
living organism (RIFAI et al., 1999). They are highly polymorphic and chemically 
diverse biomolecules, which makes it difficult to define them structurally (RIFAI et 
al., 1999). Lipids are essential for many normal functions of living organisms: they 
are important components of cell membranes, they are used to store energy, and they 
play significant roles as enzyme co-factors, hormones, and intracellular messengers 
(RIFAI et al., 1999). 
 
Of the many groups of lipids, three are most important from a clinical perspective: 
fatty acids, sterols (mainly cholesterol), and acylglyceroles (mainly triglycerides) 
(GINSBERG, 1998; RIFAI et al., 1999). Fatty acids are relatively simple lipids and 
are also important components of many other lipids. They are usually classified based 
on the length of the fatty acid chain (i.e., short chain, medium chain, and long chain 
fatty acids), and also based on their degree of saturation (i.e., saturated, 
monounsaturated, and polyunsaturated fatty acids) (GINSBERG, 1998; RIFAI et al., 
1999). Cholesterol is the main sterol in animal tissues and is almost exclusively found 
in animals. Dietary intake is the major source of cholesterol, but it can also be 
synthesized endogenously by the liver and other tissues. It plays a fundamental role in 
central metabolic pathways, such as bile acid metabolism and steroid hormone and 
vitamin D synthesis (GINSBERG, 1998; RIFAI et al., 1999). Triglycerides are the 
most common and efficient form of stored energy in mammals. They can be derived 
from both dietary sources and endogenous (hepatic) production. Each triglyceride 
consists of glycerol and three fatty acids. Triglycerides are mostly stored in 
adipocytes and, when energy is needed, fatty acids are released from triglycerides 
through the catalytic action of lipases. Oxidation of these fatty acids provides large 
amounts of energy (GINSBERG, 1998; RIFAI et al., 1999). 
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2.    Lipoproteins 
Because lipids are water-insoluble molecules, they cannot be transported in aqueous 
solutions, such as plasma. For that reason, lipids are transported in plasma as 
macromolecular complexes known as lipoproteins (MAHLEY & WEISGRABER, 
1974; WHITNEY, 1992; WATSON & BARRIE, 1993; GINSBERG, 1998; RIFAI et 
al., 1999; BAUER, 2004; JOHNSON, 2005). Lipoproteins are spherical structures 
that consist of a hydrophobic core containing lipids (i.e., triglycerides and/or 
cholesteryl esters), and an amphophilic (i.e., both hydrophobic and hydrophilic) outer 
layer of phospholipids, free cholesterol, and proteins that forms a protective envelope 
surrounding the lipid core. The amphophilic nature of the outer layer allows it to bind 
to the lipid core on one side, while the hydrophilic surface allows the lipoprotein to be 
transported in plasma (MAHLEY & WEISGRABER, 1974; BAUER, 1996; 
GINSBERG, 1998; RIFAI et al., 1999; BAUER, 2004; JOHNSON, 2005). The 
proteins that are part of the lipoproteins are known as apolipoproteins (or apoproteins) 
and play a significant role in lipid transport and metabolism (see apolipoproteins).  
 
Plasma lipoproteins differ in their physical and chemical characteristics such as size, 
density, and composition.  In addition, although lipoproteins of different species share 
common characteristics, important species differences exist (MAHLEY & 
WEISGRABER, 1974; DEMACKER et al., 1987; BAUER, 1992; BAUER, 1996; 
GINSBERG, 1998; RIFAI et al., 1999; BAUER, 2004; JOHNSON, 2005). Canine 
lipoproteins can be divided based on their hydrated density (after ultracentrifugation) 
into four major classes (Table 1): chylomicrons, very low density lipoproteins 
(VLDL), low density lipoproteins (LDL), and high density lipoproteins (HDL) 
(BAUER, 1992; WATSON & BARRIE, 1993; MALDONADO et al., 2001). HDL 
can be further subdivided into HDL1 (present only in dogs and possibly also in cats), 
HDL2 (present in dogs, cats, and humans), and HDL3 (present in dogs, cats, and 
humans) (MAHLEY & WEISGRABER, 1974; DEMACKER et al., 1987; BAUER, 
1992; WATSON & BARRIE, 1993; GINSBERG, 1998; RIFAI et al., 1999; BAUER, 
2004; JOHNSON, 2005). In human beings, a class of intermediate density 
lipoproteins (IDL) has also been identified, but this class of lipoproteins has not been 
described in dogs (GINSBERG, 1998; RIFAI et al., 1999). 
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Major
Lipoprotein Species Major lipids apoliporpoteins Size (nm) Density (g/mL)
chylomicron dog, cat dietary triglycerides B, C 75-1200 <0.960
VLDL dog, cat endogenous triglycerides B, C, E 30-80 0.093-1.006
LDL dog, cat phospholipids B 18-25 1.019-1.087
cholesteryl esters
HDL1 dog, possibly cat phospholipids A, C, E 10-35 1.025-1.100
cholesteryl esters
HDL2 dog, cat phospholipids A, C, E 9-12 1.063-1.100
HDL3 dog, cat phospholipids A, C 5-9 1.100-1.210
 
Table 1: Characteristics of major canine and feline plasma lipoproteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VLDL: very low density lipoproteins, LDL: low density lipoproteins, HDL: high density lipoproteins
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3.    Apolipoproteins 
As mentioned earlier, apolipoproteins are the protein components of lipoproteins. The 
most important classes of apolipoproteins are apolipoprotein A (apo A), 
apolipoprotein B (apo B), apolipoprotein C (apo C), and apolipoprotein E (apo E) 
(GINSBERG, 1998; RIFAI et al., 1999; BAUER, 2004; JOHNSON, 2005). Each one 
of these classes can be further divided into specific apolipoproteins (Table 2). 
Lipoproteins can contain one or a variety of different apolipoproteins, which regulate 
their metabolic functions (BAUER, 2004). 
 
Apolipoproteins are involved in several physiological functions of lipoproteins such 
as facilitation of lipid transport, maintenance of structural integrity, and activation of 
certain enzymes that play key roles in lipid metabolism (Table 2) (GINSBERG, 1998; 
RIFAI et al., 1999; BAUER, 2004; JOHNSON, 2005). For example, apo C-II is a 
necessary activator of lipoprotein lipase (the major enzyme that hydrolyzes the 
triglycerides in lipoproteins), while apo C-III inhibits lipoprotein lipase. Deficiencies 
of certain apolipoproteins have been documented mostly in humans, and usually result 
in a dysfunctional lipid metabolism. 
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Apolipoprotein Molecular weight Lipoproteins Major metabolic function
Apo A-I 28 016 HDL, chylomicrons structural, LCAT activator
Apo A-II 17 414 HDL, chylomicrons unkown
Apo A-IV 46 465 HDL, chylomicrons unkown
Apo B-48 264 000 Chylomicrons secretion of chylomicrons from intestine
Apo B-100 540 000 VLDL, IDL, LDL secretion of VLDL from the liver, structural
Apo C-I 6630 chylomicrons, VLDL, IDL, HDL uncertain
Apo C-II 8900 chylomicrons, VLDL, IDL, HDL activator of lipoprotein lipase
Apo C-III 8800 chylomicrons, VLDL, IDL, HDL inhibitor of lipoprotein lipase
Apo E 34 145 chylomicrons, VLDL, IDL, HDL facilitates uptake of chylomicron remnants
Apo (a) 250 000-800 000 Lp (a) uncertain
Table 2: Classification and properties of major human plasma apolipoproteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Apo: apolipoprotein, HDL: high density lipoproteins, VLDL: very low density lipoproteins, IDL: intermediate density lipoproteins,  
LDL: low density lipoproteins, Lp (a): lipoprotein a 
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3.1.    Apolipoprotein C-II 
The presence of a factor in plasma that activates lipoprotein lipase was first suspected 
in 1955 by Korn (KORN, 1955). About 15 years later, apo C-II was identified as an 
activator of lipoprotein lipase in plasma (HAVEL et al., 1970; LAROSA et al., 1970). 
Human apo C-II is made up of a single polypeptide chain that consists of 79 amino 
acids. However, the mature apolipoprotein is 73 amino acids long and is a product of 
proteolytic cleavage of the original polypeptide chain (FOJO et al., 1986). The human 
apo C-II gene is located on chromosome 19, has 4 exons, and encodes a polypeptide 
chain of 101 amino acids that includes a 22 amino acid signal peptide (FOJO et al., 
1984; FOJO et al., 1986; FOJO et al., 1987). Apolipoprotein C-II deficiency was first 
described in 1978 by Breckenridge et al. in a human patient with severe 
hypertriglyceridemia (BRECKENRIDGE et al., 1978). Since then several reports of 
apo C-II deficient patients have been published, and the abnormal apo C-II protein has 
been sequenced (YAMAMURA et al., 1979; MILLER et al., 1981; STALENHOEF et 
al., 1981; CATAPANO et al., 1983; SAKU et al., 1984; BAGGIO et al., 1986; 
CONNELLY et al., 1987a; CONNELLY et al., 1987b). However, it wasn’t until 1988 
when the DNA sequence of the apo C-II gene was described in human patients with 
hypertriglyceridemia (COX et al., 1988; FOJO et al., 1988b). To date, at least 16 
mutations of the apo C-II gene have been reported in humans (COX et al., 1988; 
FOJO et al., 1988a; FOJO et al., 1988b; FOJO et al., 1989a; FOJO et al., 1989b; 
CRECCHIO et al., 1990; HEGELE et al., 1991; XIONG et al., 1991; PARROTT et 
al., 1992; INADERA et al., 1993; PULLINGER et al., 1993; STREICHER et al., 
1996; DE GRAAF et al., 2000; WILSON et al., 2003; LAM et al., 2006). Mutations 
of the apo C-II gene have not been reported in dogs. 
4.    Plasma lipid enzymes 
4.1.    Lipoprotein lipase 
Lipoprotein lipase is an enzyme that hydrolyzes triglycerides within lipoproteins into 
free fatty acids, mono- and diglycerides, and glycerol. Lipoprotein lipase is 
synthesized primarily in adipose tissue and skeletal muscle and is transported to the 
luminal surface of the capillary endothelial cells (NILSSON-EHLE et al., 1980; 
Literature review 
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CRYER, 1981; SEMENKOVICH et al., 1989; WANG & HARTSUCK, 1992). The 
adhesion of this enzyme to the endothelium is facilitated by heparan sulfated 
proteoglycans, which can be competed by heparin (CRYER, 1981; WANG & 
HARTSUCK, 1992). Apolipoprotein C-II (found in chylomicrons and VLDL) is an 
important co-factor of lipoprotein lipase (CRYER, 1981; AMEIS et al., 1992; WANG 
& HARTSUCK, 1992; GINSBERG, 1998; RIFAI et al., 1999; BAUER, 2004; 
JOHNSON, 2005). Lipoprotein lipase activity is hormonally controlled and is 
regulated dependant on tissue energy requirements (BEN ZEEV et al., 1983). The 
crucial role of lipoprotein lipase in lipoprotein metabolism has been demonstrated in 
experimental animals (knockout mice), cats, dogs, and humans with lipoprotein lipase 
deficiency, which leads to severe hypertriglyceridemia (BAUM, 1969; LEES et al., 
1973; BRUNZELL et al., 1986; JONES et al., 1986a; JONES et al., 1986b; HUBERT 
et al., 1987; PERITZ et al., 1990; HAYDEN et al., 1994; COLEMAN & SEIP, 1995; 
WEINSTOCK, 1995; BIJVOET & GAGNE, 1996; MURTHY et al., 1996; 
GINZINGER & CLEE, 1999).   
4.2.    Hepatic triglyceride lipase 
Hepatic triglyceride lipase, also known as hepatic lipase, is a glycoprotein synthesized 
by hepatocytes and is located on endothelial cells of hepatic sinusoids, but also on 
endothelial cells of several extrahepatic tissues ( FROST et al., 1982; LAPOSATA et 
al., 1987; CONNELLY, 1999). In contrast to lipoprotein lipase, hepatic lipase does 
not require the presence of a co-factor for enzymatic activity (LAROSA et al., 1972). 
It is involved in hepatic uptake of triglycerides and phospholipids from chylomicrons 
and VLDL remnants, and also in the conversion of VLDL to LDL (NILSSON-EHLE 
et al., 1980; JENSEN et al., 1982; CONNELLY, 1999). In addition, hepatic lipase 
may be the major enzyme responsible for the conversion of HDL2 to HDL3 
(NIKKILA, 1981). Thus hepatic lipase plays a crucial role in triglyceride removal 
from the circulation and deficiency of this enzyme has been associated with the 
development of premature atherosclerosis (BRECKENRIDGE et al., 1982; 
CONNELLY & HEGELE, 1998). 
Literature review 
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4.3.    Lecithin-cholesterol acyl transferase (LCAT) 
LCAT is a glycoprotein synthesized primarily by the liver, which circulates in the 
blood mainly bound to HDL (TALL, 1990; FIELDING & FIELDING, 1995; JONAS, 
2000). LCAT acts on HDL molecules to convert cholesterol into cholesteryl esters. 
The newly formed cholesteryl esters move to the core of the HDL molecule, thus 
allowing more cholesterol to be transferred from tissues into HDL molecules (TALL, 
1990; FIELDING & FIELDING, 1995; JONAS, 2000; BAUER, 2004; JOHNSON, 
2005). Through this function, LCAT plays a crucial role in a pathway known as 
reverse cholesterol transport. Reverse cholesterol transport is very important because, 
through this pathway, cholesterol is transferred from peripheral tissues to the liver for 
reuse or excretion (FIELDING & FIELDING, 1995). At least 40 mutations of the 
LCAT gene have been reported in humans, and are associated with greatly decreased 
plasma HDL concentrations and susceptibility to coronary heart disease 
(KUIVENHOVEN et al., 1997; CALABRESI et al., 2005). 
4.4.    Cholesteryl ester transfer protein (CETP) 
In humans, CETP is synthesized by the liver and its major function is to transport 
triglycerides from VLDL and chylomicrons to HDL2 and cholesteryl esters (produced 
by LCAT) from HDL2 to VLDL and LDL (DECKELBAUM et al., 1982; TALL, 
1990; FIELDING & FIELDING, 1995; GINSBERG, 1998; JOHNSON, 2005). This 
results in the formation of cholesteryl ester-rich LDL and VLDL molecules and 
triglyceride-rich HDL2 (TALL, 1990; FIELDING & FIELDING, 1995; BAUER, 
2004; JOHNSON et al., 2005). However, the presence of CETP has not been 
documented in dogs and is questionable in cats (DEMACKER et al., 1987; WATSON 
et al., 1995; TSUTSUMI et al., 2001; BAUER, 2004; JOHNSON, 2005). As a result, 
cholesteryl esters produced by LCAT accumulate in canine HDL2 molecules leading 
to the formation of HDL1, which is unique to dogs (BAUER, 2004; JOHNSON, 
2005). 
5.    Lipid metabolism 
Lipid metabolism can be divided into two basic pathways: the exogenous pathway, 
which is associated with the metabolism of exogenous (dietary) lipids, and the 
Literature review 
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endogenous pathway, which is associated with metabolism of endogenously produced 
lipids (GINSBERG, 1998; RIFAI et al., 1999; BAUER, 2004). 
5.1.    Exogenous pathway 
The first step of dietary lipid metabolism (mainly metabolism of triglycerides, but 
also cholesterol and phospholipids) is digestion (BAUER, 1996; GUYTON & HALL, 
2000). Dietary lipids that reach the duodenum undergo emulsification through the 
action of bile salts and lecithin. Emulsification is crucial for subsequent digestion of 
fat because, through this procedure, the interfacial tension of the fat decreases and 
large fat globules eventually break down into smaller aggregates. This greatly 
increases the total surface area of the fat and makes it accessible for hydrolysis by 
digestive enzymes, which are water-soluble (GUYTON & HALL, 2000). 
 
Dietary triglycerides, cholesterol, and phospholipids are hydrolyzed by gastric and 
pancreatic lipases, cholesteryl ester hydrolase, and phospholipase A2, respectively 
(BAUER, 1996; GUYTON & HALL, 2000; STEINER, 2000). Triglycerides are 
mainly split into free fatty acids and 2-monoglycerides. Hydrolysis products are then 
transferred to the microvilli of the intestinal epithelial cell brush border in the form of 
micelles. At this point the fat hydrolysis products diffuse through the epithelial cell 
membranes into the enteric mucosal cells (BAUER, 1996; GUYTON & HALL, 
2000). In the intestinal mucosal cell, free fatty acids and monoglycerides reassemble 
to form new triglycerides, which then combine with phospholipids, free and esterified 
cholesterol, and apo B48 to form chylomicrons (BAUER, 1995; BAUER, 1996; 
GINSBERG, 1998; RIFAI et al., 1999; BAUER, 2004). 
 
Chylomicrons are the lipoprotein class responsible for transfer of dietary (exogenous) 
lipids. After formation in enterocytes, chylomicrons, which mainly contain 
triglycerides, are secreted into the lacteals and enter the lymphatic and later the blood 
circulation where they acquire apolipoproteins C and apo E from circulating HDL 
molecules (BAUER, 1995; BAUER, 1996; GINSBERG, 1998; RIFAI et al., 1999; 
BAUER, 2004). Apolipoprotein C-II, which is exposed on the chylomicron surface, 
activates the lipoprotein lipase attached to the capillary beds in adipose and muscle 
tissues, which then hydrolyzes triglycerides into free fatty acids and glycerol 
Literature review 
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(BAUER, 1995; BAUER, 1996; GINSBERG, 1998; RIFAI et al., 1999; BAUER, 
2004). Free fatty acids enter the muscle cells (where they are used for energy 
production) and/or adipocytes (for storage). The remaining particles, which are rich in 
cholesterol (chylomicron remnants), return their apo C-II molecule to HDL and are 
recognized by specific hepatic apo E receptors that rapidly remove them from the 
circulation by way of endocytosis (BAUER, 1995; BAUER, 1996; GINSBERG, 
1998; RIFAI et al., 1999; BAUER, 2004). The cholesterol found in chylomicron 
remnants can be used for lipoprotein (VLDL) and/or bile acid formation, or stored as 
cholesteryl ester (BAUER, 1995; BAUER, 1996). 
5.2.    Endogenous pathway 
While chylomicrons are responsible for transport of dietary lipids, VLDL, LDL, and 
HDL are mainly involved in the metabolism of endogenously produced lipids 
(BAUER, 1996). As mentioned earlier, both triglycerides and cholesterol can be 
synthesized by the liver. Endogenously synthesized triglycerides and cholesterol (and 
cholesteryl esters) combine with phospholipids and apo B100 to form VLDL (BAUER, 
1996; GINSBERG, 1998; RIFAI et al., 1999). In dogs, apo B48 is also present in 
VLDL molecules (BAUER, 2004). After VLDL molecules reach the vasculature they 
acquire apolipoproteins C and apo E from HDL (BAUER, 1995; GINSBERG, 1998; 
RIFAI et al., 1999; BAUER, 2004). As is the case for chylomicrons, VLDL apo C-II 
activates lipoprotein lipase located in capillary beds, which in turn leads to hydrolysis 
of triglycerides and the production of free fatty acids and glycerol. The VLDL 
molecules remaining after hydrolysis of VLDL triglycerides (VLDL remnants) are 
either removed from the circulation by the liver or undergo further transformation by 
lipoprotein lipase and/or hepatic lipase to form LDL (BAUER, 1995; BAUER, 1996; 
GINSBERG, 1998; RIFAI et al., 1999; BAUER, 2004; JOHNSON, 2005). 
 
LDL, which contains mainly cholesteryl esters, circulates in the blood and binds to 
specific receptors that are widely distributed throughout tissues. This way, cholesterol 
is delivered to peripheral tissues in order to be used for the synthesis of steroid 
hormones and cell membranes, and for hepatic metabolism (BAUER, 1996; 
GINSBERG, 1998; RIFAI et al., 1999). 
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HDLs, which are synthesized primarily in the liver, play an important role as donors 
and acceptors of apolipoproteins C, apo E, and various lipids from other lipoproteins 
in the circulation (TALL, 1990; WATSON & BARRIE, 1993; GINSBERG, 1998; 
RIFAI et al., 1999; BAUER, 2004). They play a fundamental role in the metabolic 
pathway known as the reverse cholesterol transport pathway (WATSON & BARRIE, 
1993; FIELDING & FIELDING, 1995; GINSBERG, 1998; BAUER, 2004). Through 
this metabolic pathway, cholesterol is transferred from peripheral tissues to the small 
circulating discoid HDL molecules, thus converting them to nascent HDL3 molecules. 
Cholesterol is then esterified by the action of LCAT and cholesteryl esters move to 
the core of the HDL3 molecule thus allowing more free cholesterol to get absorbed 
into their surface. Continued absorption of free cholesterol and subsequent 
esterification by LCAT leads to the formation of the larger, cholesteryl ester-rich 
HDL2. Cholesteryl esters of HDL2 molecules are eventually delivered to the liver for 
reuse or excretion (FIELDING & FIELDING, 1995; GINSBERG, 1998; RIFAI et al., 
1999; BAUER, 2004). With this pathway, cellular and lipoprotein cholesterol is 
transferred back to the liver for reuse or disposal. In humans, an additional enzyme 
(cholesteryl ester transfer protein) is involved in this process but, as mentioned earlier, 
the presence of this enzyme has not been documented in dogs and its existence in 
questionable in cats (DEMACKER et al., 1987; WATSON & BARRIE, 1993; 
WATSON et al., 1995; GINSBERG, 1998; TSUTSUMI et al., 2001; BAUER, 2004; 
JOHNSON, 2005). The role of this enzyme is to transfer triglycerides from LDL, 
VLDL, and chylomicrons to HDL2 in exchange for cholesteryl esters. This results in 
the production of cholesteryl ester-rich LDL and triglyceride-rich HDL2 molecules 
(WATSON & BARRIE, 1993; GINSBERG, 1998; RIFAI et al., 1999; BAUER, 2004; 
JOHNSON, 2005). The absence of this enzyme in dogs might be responsible for 
certain differences in lipoprotein metabolism between this species and human beings. 
Due to absence of this enzyme, HDL2 molecules continuously acquire cholesteryl 
esters, resulting in the formation of HDL1 molecules, which are unique to dogs. On 
HDL1, cholesteryl esters are transferred from tissues to the liver for disposal or reuse 
rather than in LDL or VLDL molecules, which transfer cholesterol to peripheral 
tissues (WATSON & BARRIE, 1993; BAUER, 2004; JOHNSON, 2005). Thus, it is 
this function of HDL1 that accounts for the lower incidence of atherosclerotic 
disorders in dogs compared to humans (JOHNSON, 2005). 
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6.    Disorders of lipid metabolism 
6.1.    Definitions 
The term hyperlipidemia refers to increased concentrations of lipids (usually 
triglycerides, cholesterol, or both) in the blood (WATSON & BARRIE, 1993; FORD, 
1996; JOHNSON, 2005). More specifically, an increased blood concentration of 
triglycerides is referred to as hypertriglyceridemia, while an increased blood 
concentration of cholesterol is referred to as hypercholesterolemia. The term 
hyperlipoproteinemia refers to increased blood concentrations of lipoproteins, but it is 
often used interchangeably with the term hyperlipidemia (BAUER, 1995). However, 
the term hyperlipoproteinemia should ideally be limited to cases where measurements 
of lipoprotein concentrations have been conducted (BAUER, 1995; JOHNSON, 
2005). 
 
The term lipemia is used to describe turbid or lactescent appearance of serum or 
plasma (WATSON & BARRIE, 1993; FORD, 1996; JOHNSON, 2005). Lipemia is a 
result of hypertriglyceridemia, but not hypercholesterolemia (WATSON et al., 1993; 
BAUER, 1995; FORD, 1996; JOHNSON, 2005). Mild hypertriglyceridemia does not 
cause lipemia. Usually, lipemia is apparent when serum triglyceride concentrations 
exceed 200 - 300 mg/dL (BAUER, 1995). As serum triglyceride concentrations 
increase, serum becomes turbid (cloudy) and then lactescent (milky). 
 
Hypertriglyceridemia is a relatively common clinicopathologic finding in dogs. In a 
study of 1,022 blood samples from both healthy and diseased dogs of various breeds, 
5.4% had increased serum triglyceride concentrations, but the study did not include 
grossly lipemic samples (COMAZZI et al., 2004). Postprandial hypertriglyceridemia 
is normal and transient, and typically resolves within 7-12 hours after a meal, 
depending on the fat content of the meal (DOWNS et al., 1997; BAUER, 2004). 
Persistent fasting hypertriglyceridemia is always considered abnormal and can either 
be primary (most commonly idiopathic) or be secondary to other diseases or drug 
administration (BAUER, 2004).  
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6.2.    Laboratory evaluation of lipid disorders 
6.2.1.    Serum turbidity 
Visual evaluation of plasma or serum usually offers the first estimate of a sample’s 
triglyceride concentration. Samples that have normal or near normal serum 
triglyceride concentrations are clear, while samples with increased serum triglyceride 
concentrations are lipemic (turbid or lactescent; Figure 1) (WATSON & BARRIE, 
1993; FORD, 1996; JOHNSON, 2005). In general, turbidity appears when serum 
triglyceride concentrations are above to 200 - 300 mg/dl and lactescent serum is seen 
when serum triglyceride concentrations are above 1,000 mg/dL (BAUER, 1995; 
JOHNSON, 2005). However, these guidelines provide only a rough estimate of the 
actual serum triglyceride concentration, and measurement of the actual serum 
triglyceride concentration is required. In addition, the presence of 
hypercholesterolemia cannot be excluded on the basis of a clear serum sample 
because hypercholesterolemia does not cause increased serum turbidity (WHITNEY, 
1992; JOHNSON, 2005). 
Literature review 
 16 
   
 
 
Figure 1: Lipemia 
 
Serum samples with normal serum triglyceride concentrations are clear (left tube). As 
serum triglyceride concentration increases, the serum becomes turbid (middle tube) 
and ultimately lactescent (right tube). 
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6.2.2.    Refrigeration test 
The refrigeration test (or chylomicron test) is performed on lipemic samples, and is a 
simple test to determine the specific form of lipoprtotein that is responsible for 
hypertriglyceridemia (ROGERS, 1977; WHITNEY, 1992; JOHNSON, 2005). Serum 
samples are refrigerated and left undisturbed for 10 to 12 hours. Due to their lower 
density, chylomicrons tend to move to the top of the sample and form a “cream layer” 
(Figure 2). When a cream layer is formed, chylomicrons account (partially or solely) 
for the hypertriglyceridemia (ROGERS, 1977; WHITNEY, 1992; JOHNSON, 2005). 
If there is no cream layer formation, the hypertriglyceridemia and lipemia are due to 
an excess of other lipoproteins (usually VLDL, because these contain high 
concentrations of triglycerides) (WHITNEY, 1992; JOHNSON, 2005). When a cream 
layer forms, the serum below the cream layer can either be clear or turbid. In the first 
case, hyperchylomicronemia is most likely solely responsible for the 
hypertriglyceridemia, while in the second case other lipoproteins are also present in 
excess (Figure 2) (WHITNEY, 1992; JOHNSON, 2005). 
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Figure 2: Chylomicron test. 
 
The picture on the left shows a lipemic serum sample from a dog with 
hypertriglyceridemia right after separation of the serum from the clot. The same 
serum sample is shown on the right after overnight refrigeration (chylomicron test). 
The formation of a cream layer is obvious. The remaining serum below the cream 
layer is clear (although hemolytic), which suggests that other classes of lipoproteins 
are not increased in this patient. 
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6.2.3.    Methods for quantification and characterization of lipids in blood 
Routine quantitative assessment of total cholesterol and triglyceride concentrations in 
serum or plasma is usually achieved by use of spectrophotometric or enzymatic 
methods (NELSON et al., 2004). Lipoprotein electrophoresis has been commonly 
used to further characterize lipid abnormalities in dogs and other animals, but has 
limited use in the routine clinical evaluation of hyperlipidemic dogs (WHITNEY, 
1992; NELSON et al., 2004). Some differences of serum lipoprotein and fatty acid 
concentrations among dog breeds have been reported (DOWNS et al., 1993; SMITH 
et al., 2008). Finally, ultracentrifugation has been used to separate serum or plasma 
lipoproteins based on their density. However, due to its high cost, this method is not 
routinely used in veterinary medicine. 
 
6.3.    Causes of hyperlipidemia 
Postprandial hypertriglyceridemia is physiologic and transient, and typically resolves 
within 7-12 hours after a meal, depending on the fat content of the meal (WHITNEY, 
1992; DOWNS et al., 1997; BAUER, 2004; JOHNSON, 2005). For that reason, 
determination of serum lipid concentrations should always follow a fast of at least 12 
hours. Persistent fasting hypertriglyceridemia is always considered abnormal and can 
either be primary (idiopathic) or secondary due to other diseases or drug 
administration.  
 
6.3.1.    Secondary causes of hyperlipidemia 
Secondary hyperlipidemia is the most common pathologic form of hyperlipidemia in 
dogs (NELSON et al., 2004). Several diseases have been reported to cause 
hyperlipidemia.  
 
6.3.1.1.    Endocrine Diseases 
Most commonly, canine hyperlipidemia is the result of an endocrine disorder, such as 
hypothyroidism, diabetes mellitus, or hyperadrenocorticism (ROGERS et al., 1975b; 
ROGERS, 1977; WHITNEY, 1992; BAUER, 2004; FELDMAN & NELSON, 2004; 
JOHNSON, 2005). Increases of both serum triglyceride and cholesterol 
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concentrations have been reported in dogs with hypothyroidism (ROGERS et al., 
1975b; BARRIE et al., 1993; PANCIERA, 1994; DIXON et al., 1999; SCHENCK et 
al., 2004). In one study, hypertriglyceridemia and hypercholesterolemia were found in 
88% and 78% of dogs with hypothyroidism, respectively (DIXON et al., 1999). 
Usually, lipid abnormalities resolve after treatment of hypothyroidism (ROGERS et 
al., 1975b). Dogs with diabetes mellitus commonly have hyperlipidemia, which is 
most commonly associated with hypertriglyceridemia, although hypercholesterolemia 
might also be present (ROGERS et al., 1975b; WILSON et al., 1986; WHITNEY, 
1992; BARRIE et al., 1993; FELDMAN & NELSON, 2004; JOHNSON, 2005). 
Hypertriglyceridemia usually resolves after successful treatment of diabetes, but 
hypercholesterolemia might persist despite therapy (GLEESON et al., 1990; 
WHITNEY, 1992). Finally, both naturally occurring and iatrogenic 
hyperadrenocorticism have been associated with hyperlipidemia 
(hypertriglyceridemia and hypercholesterolemia) in dogs (LING et al., 1979; 
WHITNEY, 1992; BARRIE et al., 1993; HUANG et al., 1999; BAUER, 2004; 
FELDMAN & NELSON 2004; JOHNSON, 2005). Hypertriglyceridemia appears to 
be present more frequently than hypercholesterolemia in dogs with 
hyperadrenocorticism, and increases of both types of lipids are usually mild or 
moderate (BAUER, 2004; FELDMAN & NELSON 2004; JOHNSON, 2005). 
 
6.3.1.2.    Pancreatitis 
The presence of hyperlipidemia (hypertriglyceridemia and, to a lesser degree, 
hypercholesterolemia) has long been associated with naturally occurring pancreatitis 
in dogs (ANDERSON & LOW, 1965; ANDERSON & STRAFUSS, 1971; ROGERS 
et al., 1975b; ROGERS, 1977; WHITNEY, 1992; COOK et al., 1993; HESS et al., 
1998; HESS et al., 1999; BAUER, 2004; JOHNSON, 2005; WILLIAMS & 
STEINER, 2005). However, it remains uncertain whether hyperlipidemia develops as 
a result of pancreatitis or can be the cause of pancreatitis in some cases (WHITNEY, 
1992; WILLIAMS & STEINER, 2005). In one study where acute pancreatitis was 
experimentally induced in dogs by intraductal infusion of bile and lyophilized trypsin, 
neither hypertriglyceridemia nor hypercholesterolemia developed up to 96 hours after 
induction of pancreatitis (WHITNEY et al., 1987). Similar results were reported in an 
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older study where pancreatitis was induced in dogs by ligation of the major and minor 
pancreatic ducts (BASS et al., 1976). In this study, pancreatitis did not result in 
hypertriglyceridemia or hypercholesterolemia up to 14 days after induction (BASS et 
al., 1976). In a more recent study, mild increases in serum triglyceride concentrations 
were noted in dogs after induction of pancreatitis with oleic acid (CHIKAMUNE et 
al., 1998). Although serum triglyceride concentrations significantly increased, they 
seemed to remain within the reference range even after induction of pancreatitis 
(CHIKAMUNE et al., 1998). However, this is not clearly discussed in this report 
(CHIKAMUNE et al., 1998). Based on these studies, it can be concluded that 
hypertriglyceridemia is not a feature of experimentally induced pancreatitis in dogs. 
No conclusive statement regarding the role of naturally occurring pancreatitis in the 
development of secondary hyperlipidemia can be made. Given the documented 
association between naturally occurring pancreatitis and hyperlipidemia, it is possible 
that either hyperlipidemia is a preexisting abnormality in some dogs with naturally 
occurring pancreatitis, which may or may not contribute to the development of the 
disease, or that naturally occurring pancreatitis differs from the experimental models 
of pancreatitis used in the above studies in its ability to produce hyperlipidemia. 
 
6.3.1.3.    Obesity 
Increased serum triglyceride and/or cholesterol concentrations have been observed in 
obese dogs (CHIKAMUNE et al., 1995; BAILHACHE et al., 2003; JEUSETTE et al., 
2005). The most profound lipid abnormalities were associated with severe chronic 
obesity (JEUSETTE et al., 2005). Weight loss in obese dogs leads to significant 
decreases of both serum triglyceride and cholesterol concentrations (DIEZ et al., 
2004; JEUSETTE et al., 2005). 
 
6.3.1.4.    Protein losing nephropathy (PLN) 
Proteinuria associated with PLN, regardless of the cause, is often associated with 
hyperlipidemia in dogs (CHEW et al., 1983; CENTER et al., 1987; DIBARTOLA et 
al., 1989; DIBARTOLA et al., 1990; REUSCH et al., 1994; COOK & COWGILL, 
1996; DE MORAIS et al., 1996; LITTMAN et al., 2000). The most commonly 
reported lipid abnormality in dogs with PLN is hypercholesterolemia, which is usually 
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mild or moderate (CHEW et al., 1983; CENTER et al., 1987; DIBARTOLA et al., 
1989; DIBARTOLA et al., 1990; REUSCH et al., 1994; COOK & COWGILL, 1996; 
DE MORAIS et al., 1996; LITTMAN et al., 2000). Hypercholesterolemia in dogs 
with PLN is usually part of a more complex syndrome, the nephrotic syndrome, 
which in addition to hypercholesterolemia, is characterized by hypoalbuminemia, 
proteinuria, and ascites (BAUER, 2004; JOHNSON, 2005). Hypercholesterolemia has 
been reported with varying frequencies in dogs with acquired glomerular disease 
(amyloidosis or glomerulonephritis) and proteinuria, as well as several hereditary 
forms of PLN (Chinese Shar-peis, Golden Retrievers, Soft-coated Wheaten Terriers, 
Doberman Pinschers, and Bernese Mountain dogs) (CHEW et al., 1983; CENTER et 
al., 1987; DIBARTOLA et al., 1989; DIBARTOLA et al., 1990; REUSCH et al., 
1994; COOK & COWGILL, 1996; DE MORAIS et al., 1996; LITTMAN et al., 
2000). 
 
6.3.1.5.    Cholestasis 
Cholestasis has been reported to lead to mild or moderate hypercholesterolemia and 
mild hypertriglyceridemia in dogs (DANIELSSON et al., 1977; WHITNEY, 1992; 
CHUANG et al., 1995). Changes in lipoproteins, mainly excessive esterification of 
lipoprotein cholesterol, have also been reported in dogs with experimentally induced 
cholestasis (BLOMHOFF et al., 1978; WALLI & SEIDEL, 1984). 
 
6.3.1.6.    Other causes 
Several other causes of hyperlipidemia have been reported or suspected to exist in 
dogs. These include high fat diets, lymphoma, infection with Leishmania infantum, 
congestive heart failure due to dilated cardiomyopathy, and administration of certain 
drugs (e.g., glucocorticoids) (NIETO et al., 1992; OGILVIE et al., 1994; 
BURKHARD & MEYER, 1995; DOWNS et al., 1997; TIDHOLM & JONSSON, 
1997). Finally, in a recent study, significantly increased serum triglyceride 
concentrations were reported in association with other lipid abnormalities in dogs 
with parvoviral enteritis (YILMAZ & SENTURK, 2007). 
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6.3.2.    Primary causes of hyperlipidemia in dogs 
In general, primary lipid abnormalities have not been sufficiently studied in dogs. 
They appear to be rare and are usually, but not always, associated with specific 
breeds. Primary hyperlipidemia in Miniature Schnauzers was the first breed-related 
primary lipid disorder described in dogs, and is believed to be the most common 
(ROGERS et al., 1975a; WHITNEY, 1992; FORD, 1993; WHITNEY et al., 1993; 
BAUER, 1995; BAUER, 2004). This condition was first reported more than 30 years 
ago in Miniature Schnauzers in the United States, but has not been documented 
elsewhere (ROGERS et al., 1975a; WHITNEY, 1992; FORD, 1993; WHITNEY et 
al., 1993; BAUER, 1995; BAUER, 2004). It is characterized by abnormal 
accumulation of VLDL or a combination of VLDL and chylomicrons (FORD, 1993; 
WHITNEY et al., 1993). Although hypercholesterolemia may also be present, this 
finding is not consistent (WHITNEY, 1992; FORD, 1993; WHITNEY et al., 1993). 
The cause of hypertriglyceridemia in Miniature Schnauzers remains unclear, but 
possible mechanisms include increased production and/or decreased clearance of 
VLDL and chylomicrons (FORD, 1993; BAUER, 1995; FORD, 1996). The fact that 
hypertriglyceridemia is prevalent within a single breed suggests a possible hereditary 
mechanism (ROGERS et al., 1975a; FORD, 1993; WHITNEY et al., 1993). Because 
lipoprotein lipase is the major enzyme involved in triglyceride clearance, deficiency 
of this enzyme has been considered as a possible cause of hypertriglyceridemia in this 
breed. Two studies that included both Miniature Schnauzers and dogs of other breeds 
with primary hyperlipidemia, found that lipoprotein lipase activity was significantly 
lower in plasma from hyperlipidemic dogs than in healthy control dogs (SCHENCK, 
2002; JAEGER et al., 2003). However, a recent study in Miniature Schnauzers with 
hypertriglyceridemia and pancreatitis failed to identify any mutations of the 
lipoprotein lipase gene, suggesting that inherited lipoprotein lipase dysfunction is not 
the cause of hypertriglyceridemia in this breed (SCHICKEL, 2005a). Further studies 
are warranted to identify the genetic basis of idiopathic hypertriglyceridemia in 
Miniature Schnauzers. 
 
Primary hypercholesterolemia without hypertriglyceridemia has been well 
documented in 15 Briards from the UK (WATSON et al., 1993). A similar condition 
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has recently been described in a family of rough Collies also from the UK 
(JEUSETTE et al., 2004) A slightly different condition of primary 
hypercholesterolemia with or without concurrent hypertriglyceridemia has been 
reported in Shetland Sheepdogs in Japan (SATO et al., 2000). The cause of these lipid 
abnormalities that mainly involve cholesterol metabolism cannot be determined based 
on these studies, but hereditary factors have been suspected (SATO et al., 2000; 
WATSON et al., 1993). In addition, primary hypercholesterolemia has been 
anecdotally reported in Doberman Pinschers and Rottweilers (ARMSTRONG & 
FORD, 1989). 
 
Primary hyperlipidemia with hypercholesterolemia and hypertriglyceridemia has been 
reported in two related Beagles (WADA et al., 1977). Also, primary 
hypertriglyceridemia has been reported in two related adult Brittany Spaniels and one 
mixed-breed 28-day old puppy. In all 3 cases, lipoprotein lipase deficiency was 
suspected based on a deficient or absent lipoprotein lipase activity after heparin 
administration (BAUM, 1969; HUBERT et al., 1987).  
 
6.4.    Clinical signs and complications of hyperlipidemia  
In general, dogs with secondary hyperlipidemia display clinical signs associated with 
the primary disorder. Dogs with primary lipid disorders are often asymptomatic for 
long periods or even throughout their lives. However, in some cases, dogs with 
primary hyperlipidemia develop secondary diseases as a result of hyperlipidemia that 
may account for the development of specific clinical signs. Whether or not dogs with 
primary hyperlipidemia will develop clinical signs depends on many factors, 
including the type and severity of hyperlipidemia, and the presence or absence of 
other diseases. 
 
6.4.1.    Pancreatitis 
An association between hyperlipidemia and pancreatitis was first noted by Speck in 
1865 (SPECK, 1865). Today, severe hypertriglyceridemia is a known risk factor for 
the development of pancreatitis in humans (CAMERON et al., 1974; TOSKES, 1990; 
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FORTSON et al., 1995; YADAV & PITCHUMONI, 2003). Although hyperlipidemia 
has been reported in up to 38% of human patients with pancreatitis, in the vast 
majority of these patients, hyperlipidemia is mild and is likely the result rather than 
the cause of pancreatitis (TOSKES, 1990; FORTSON et al., 1995; YADAV & 
PITCHUMONI, 2003). An increased risk for pancreatitis from hyperlipidemia has 
been shown to exist when serum triglyceride concentrations exceed 1,000 mg/dL, 
which is most commonly associated with primary defects in lipid metabolism 
(TOSKES, 1990; FORTSON et al., 1995; YADAV & PITCHUMONI, 2003). Lipid 
disorders most commonly associated with pancreatitis in humans are lipoprotein 
lipase or apo C-II deficiency, familial combined hyperlipidemia, and familial 
hypertriglyceridemia (TOSKES, 1990; YADAV & PITCHUMONI, 2003). The latter 
2 conditions occur much more frequently than lipoprotein lipase or apo C-II 
deficiency, but the underlying genetic defects have not yet been determined 
(TOSKES, 1990; YADAV & PITCHUMONI, 2003). In cases where secondary 
hyperlipidemia is severe (i.e., >1,000 mg/dL) or if it is combined with a primary lipid 
disorder, it can potentially also lead to pancreatitis. For example, hyperlipidemic 
pancreatitis has been found to occur more commonly in patients with poorly 
controlled or untreated diabetes or diabetic ketoacidosis (FORTSON et al., 1995; 
NAIR et al., 2000). Hypercholesterolemia does not constitute a risk factor for 
pancreatitis in humans (TOSKES, 1990). The mechanism by which 
hypertriglyceridemia (primary or secondary) induces pancreatitis is not clear. A 
possible mechanism is that serum triglycerides are hydrolyzed by the action of 
pancreatic lipase, leading to excessive production of free fatty acids, which are toxic 
to the pancreas (HAVEL, 1969; SAHARIA et al., 1977). To date, there are no means 
to predict which hyperlipidemic patients will develop pancreatitis, and the clinical 
course of hyperlipidemic pancreatitis is no different from other forms of pancreatitis 
in humans (TOSKES, 1990; YADAV & PITCHUMONI, 2003). 
 
A similar relationship between hypertriglyceridemia and pancreatitis has been 
suggested in dogs (ROGERS et al., 1975a; ROGERS, 1977; WHITNEY, 1992; 
FORD, 1993; BAUER, 1995; FORD, 1996; WILLIAMS, 1996; BAUER, 2004; 
WILLIAMS & STEINER, 2005). In addition, the clinical impression of a high 
prevalence of pancreatitis in Miniature Schnauzers has been attributed to the fact that 
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dogs of this breed commonly develop hyperlipidemia (WHITNEY, 1992; FORD, 
1996; WILLIAMS, 1996; WILLIAMS & STEINER, 2005). Available clinical and 
experimental data to support this hypothesis are limited, however. Pancreatitis has 
been shown to develop in dogs after feeding high fat, low protein diets, and is more 
severe when induced in dogs being fed a high fat diet (LINDSAY et al., 1948; 
GOODHEAD, 1971). Also, experimental data in isolated canine pancreas showed that 
high triglyceride concentrations can induce pancreatitis, possibly through the release 
of free fatty acids (SAHARIA et al., 1977). Clinical studies have shown an 
association between hyperlipidemia and pancreatitis in dogs, although it was not 
determined whether hyperlipidemia was the cause or the result of pancreatitis, or just 
an incidental finding in some cases (ROGERS et al., 1975a; ROGERS et al., 1975b; 
WHITNEY et al., 1987; COOK et al., 1993; HESS et al., 1998; HESS et al., 1999; 
WILLIAMS & STEINER, 2005). Secondary hyperlipidemia seen in patients with 
some endocrinopathies (e.g., hypothyroidism, hyperadrenocorticism, or diabetes 
mellitus), may be responsible for the increased risk for pancreatitis associated with 
these diseases (HESS et al., 1999; HESS et al., 2000). Also, hyperlipidemia has been 
observed in obese dogs, suggesting a possible explanation for why obese dogs are 
more prone to pancreatitis (CHIKAMUNE et al., 1995; HESS et al., 1999). Based on 
these studies, an association between hypertriglyceridemia and pancreatitis in dogs is 
obvious, but a cause-and-effect relationship cannot be established. Further studies are 
needed in order to evaluate hypertriglyceridemia as a risk factor for pancreatitis in 
dogs.  
 
6.4.2.    Atherosclerosis 
Hyperlipidemia, and especially hypercholesterolemia, is recognized as a major risk 
factor for the development of atherosclerosis in humans (SCHOEN & COTRAN, 
1999). Although dogs are resistant to atherosclerosis due to their lipoprotein 
composition and metabolism, they have been reported to develop atherosclerosis in 
both experimental and clinical studies (MAHLEY et al., 1974; MAHLEY et al., 1977; 
LIU et al., 1986; KAGAWA et al., 1998; HESS et al., 2003). Spontaneous 
atherosclerosis has been reported in dogs mainly in association with secondary 
hyperlipidemia (LIU et al., 1986; HESS et al., 2003). In these cases, atherosclerosis 
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has been thought to develop as a result of hypercholesterolemia (KAYSEN et al., 
1986; HESS et al., 2003). The most commonly reported disorders associated with 
spontaneous atherosclerosis in dogs are endocrinopathies that are associated with 
hypercholesterolemia (HESS et al., 2003; VITALE & OLBY, 2007). In one study, 
60% of 30 dogs with atherosclerosis had hypothyroidism, and 20% had diabetes 
mellitus (HESS et al., 2003). However, in the same study, 23% of the dogs with 
atherosclerosis did not have any endocrine disorder associated with 
hypercholesterolemia, which suggests that atherosclerosis can also develop secondary 
to other diseases (HESS et al., 2003). It is currently not known whether primary 
hyperlipidemia can also be associated with atherosclerosis in dogs (HESS et al., 
2003).  
 
6.4.3.    Insulin resistance and diabetes mellitus 
In human beings, severe hypertriglyceridemia has been reported to be related to 
insulin resistance and the development of diabetes mellitus (SANE & TASKINEN, 
1993; MINGRONE et al., 1997; MINGRONE et al., 1999). Families with hereditary 
hypertriglyceridemia have a high incidence of type 2 diabetes (21% in one 10-year 
study) (SANE & TASKINEN, 1993). In these families, hyperlipidemic family 
members were more likely to develop type 2 diabetes, and increased serum 
triglyceride concentrations were a risk factor for glucose intolerance and type 2 
diabetes (SANE & TASKINEN, 1993). In another study, severely increased serum 
triglyceride concentrations were shown to induce insulin-resistant diabetes mellitus in 
humans (MINGRONE et al., 1999). In addition, correction of hypertriglyceridemia in 
obese patients with diabetes has been shown to improve glucose utilization and 
enhance insulin sensitivity (MINGRONE et al., 1997). In vitro studies show that 
increased nonesterified fatty acid (NEFA) concentrations result in insulin 
hypersecretion by cultured islet cells at low glucose concentrations (MILBURN et al., 
1995). Collectively, above data suggest that hypertriglyceridemia and/or increased 
NEFA concentrations can lead to insulin resistance and type 2 diabetes mellitus in 
humans. The role of hypertriglyceridemia as a risk factor for the development of 
diabetes mellitus has not been studied in dogs.  
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6.4.4.    Liver disease 
In human beings, hypertriglyceridemia has been associated with the development of 
fatty liver and a condition known as NAFLD (ASSY et al., 2000; ANGULO, 2002; 
NEUSCHWANDER-TETRI & CALDWELL, 2003; DE BRUIN et al., 2004; 
BROUWERS et al., 2007). This condition is characterized by excessive lipid 
deposition in hepatocytes with or without concurrent inflammation, fibrosis, and 
cirrhosis in the absence of alcohol abuse (ANGULO, 2002). The pathogenesis of fatty 
liver and NAFLD is not completely understood, but is believed to involve several 
factors, including hypertriglyceridemia, that can potentially lead to substantial lipid 
deposition in hepatocytes (ANGULO, 2002; NEUSCHWANDER-TETRI & 
CALDWELL, 2003). The prevalence of fatty liver in patients with hyperlipidemia, 
including both hypertriglyceridemia and hypercholesterolemia, has been reported to 
be about 50% (ASSY et al., 2000; BROUWERS et al., 2007). However, 
hypertriglyceridemia has been found to be a more useful predictor of fatty liver and, 
in 1 study, about 70% of patients with hypertriglyceridemia were found to have 
ultrasonographic evidence of fatty infiltration of the liver or NAFLD (ASSY et al., 
2000). Most human patients with NAFLD remain asymptomatic for long periods, and 
many of these patients have only abnormally high liver enzyme activities as the initial 
manifestation of NAFLD (ASSY et al., 2000; ANGULO, 2002; NEUSCHWANDER-
TETRI & CALDWELL, 2003). Liver enzyme activities are usually only mildly 
increased (i.e., < 2 times the upper reference limit) and are typically identified during 
routine screening (ANGULO, 2002; NEUSCHWANDER-TETRI & CALDWELL, 
2003). Studies investigating a possible association between hypertriglyceridemia, high 
serum liver enzyme activities, and liver disease in dogs have not been described.  
 
Clinical studies and anecdotal observations suggest that two conditions of the liver 
might be associated with hypertriglyceridemia in dogs: vacuolar hepatopathy and 
gallbladder mucocele (CENTER, 1996b; SCHERK & CENTER 2005). Vacuolar 
hepatopathy shares some common characteristics with certain types of NAFLD, such 
as the fact that both can be asymptomatic for long periods and that histopathologically 
they are characterized by vacuole formation of hepatocytes (CENTER, 1996b; 
NEUSCHWANDER-TETRI & CALDWELL, 2003; HUBSCHER, 2006). 
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Gallbladder mucocele has been commonly reported in dog breeds that are predisposed 
to idiopathic hyperlipidemia (e.g., Miniature Schnauzers and Shetland Sheepdogs) 
and hyperlipidemia has been implicated in gallbladder disease in humans (BOLAND 
et al., 2002; PIKE et al., 2004; AGUIRRE et al., 2007). A clear association between 
the presence of hyperlipidemia and gallbladder mucocele formation had not been 
described in dogs, however. In a recent study, an association between gallbladder 
mucocele formation and dyslipidemias (hypertriglyceridemia and 
hypercholesterolemia) was described in Shetland Sheepdogs (AGUIRRE et al., 2007). 
In this study, many of the dogs with a gallbladder mucocele were found to have no 
clinical signs or biochemical abnormalities, except for an increased serum ALP 
activity in some cases (AGUIRRE et al., 2007). The relationship between different 
forms of hyperlipidemia and liver and gallbladder diseases in dogs needs further 
investigation. 
 
6.4.5.    Ocular disease  
Lipemia retinalis has been reported to occur as a result of severe (typically >1,000 
mg/dL) primary or secondary hypertriglyceridemia in humans (SHAH et al., 2001; 
LU et al., 2005). This condition is characterized by lipid accumulation in the retinal 
vessels, which turn white and can be differentiated only by their size (SHAH et al., 
2001; LU et al., 2005). Vision is usually not affected in this condition (SHAH et al., 
2001; LU et al., 2005). Cases of lipemia retinalis have been reported mainly in cats 
with hypertriglyceridemia due to lipoprotein lipase deficiency, and in one dog with 
pancreatitis (BRIGHTMAN et al., 1980; JONES et al., 1986a; JONES et al., 1986b). 
Other ocular manifestations of hyperlipidemia, such as lipemic aqueous and lipid 
keratopathy have also been reported in dogs (CRISPIN, 1993). Recently, solid 
intraocular xanthogranuloma formation was reported as a unique disorder of 
hyperlipidemic Miniature Schnauzers (ZAFROSS & DUBIELZIG, 2007). Diabetic 
Miniature Schnauzers with hyperlipidemia were also considered to be at increased 
risk for the development of uveitis and glaucoma (ZAFROSS & DUBIELZIG, 2007).  
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6.4.6.    Other possible complications of hyperlipidemia 
Seizures have been reported to occur as a result of hypertriglyceridemia in dogs 
(ROGERS et al., 1975a; BODKIN, 1992; BAUER, 1995). In a recent study, severe 
hyperlipidemia (both hypertriglyceridemia and hypercholesterolemia) was reported as 
a possible cause of neurologic signs in 4 Labrador Retrievers with hypothyroidism 
(VITALE & OLBY, 2007). In this study, diagnostic imaging studies related 
neurologic signs to vascular lesions in 2 dogs (VITALE & OLBY, 2007). However, 
the relationship between hyperlipidemia and neurologic disorders remains obscure in 
dogs.  
 
Some authors report that hyperlipidemia can cause clinical signs of abdominal pain, 
lethargy, vomiting, and/or diarrhea, without evidence of pancreatitis or other diseases 
(FORD, 1993; FORD, 1996). This is highly speculative, however, because published 
reports are lacking and, given the difficulty in diagnosing pancreatitis especially in 
past decades, pancreatitis could easily have been missed. Finally, cutaneous 
xanthomas and peripheral neuropathies have also been reported, mainly in cats with 
lipoprotein lipase deficiency (JONES et al., 1986b). 
 
6.5.    Treatment of hyperlipidemia 
The first step in the treatment of canine hyperlipidemia is the determination of 
whether the patient has a primary or a secondary lipid disorder (ROGERS, 1977; 
FORD, 1996; JOHNSON, 2005). Thus, specific diagnostic investigation should be 
performed in order to diagnose or rule out diseases that can cause secondary 
hyperlipidemia. Treatment of secondary hyperlipidemia relies on successful treatment 
of the primary disorder, after which hyperlipidemia usually resolves (ROGERS, 1977; 
WHITNEY, 1992; FORD, 1996; JOHNSON, 2005). 
 
After secondary causes of hyperlipidemia have been ruled out, a presumptive 
diagnosis of a primary lipid disorder can be made (WHITNEY, 1992). It has been 
recommended that hypertriglyceridemia that exceeds 500 mg/dL should be treated in 
order to avoid possible complications (WHITNEY, 1992; FORD, 1996). It also has 
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been recommended that the treatment goal should be to keep serum triglyceride 
concentrations below 500 mg/dL (FORD, 1996). Primary hypercholesterolemia is 
usually associated with less severe complications compared to hypertriglyceridemia. 
Therefore, correction of hypercholesterolemia is only recommended when serum 
cholesterol concentrations are severely increased (FORD, 1996). 
 
6.5.1.    Dietary management 
Typically, the first step in the management of primary hyperlipidemia is dietary 
modification (ROGERS, 1977; WHITNEY, 1992; FORD, 1996; JOHNSON, 2005). 
Dogs with primary hyperlipidemia should be offered a low fat diet throughout their 
lives (FORD, 1996). Especially dogs with hyperchylomicronemia (i.e., most 
Miniature Schnauzers with primary hyperlipidemia) will typically benefit from low 
fat diets because chylomicrons are a result of dietary fat absorption (ROGERS, 1977; 
BAUER, 1995; FORD, 1996). Diets that contain less than 20% fat on a metabolic 
energy basis are recommended (FORD, 1996; ELLIOTT, 2005; JOHNSON, 2005). 
Many commercially available diets are suitable for dogs with primary hyperlipidemia. 
Treats and table scraps should be avoided unless they are low in fat (ELLIOTT, 
2005). Serum lipid concentrations should be re-evaluated after feeding a low fat diet 
for about 4 weeks (FORD, 1996). If serum triglyceride concentrations have decreased 
to < 500 mg/dL, dietary therapy should be continued and the new diet should be 
offered for the rest of the animal’s life, and serum triglyceride concentrations should 
be re-evaluated every 6 to 12 months (FORD, 1996). However, some animals will not 
sufficiently respond to low fat diets. In these cases, an ultra low fat home-made diet 
(e.g., 10% of fat on a metabolic energy basis) can be offered, or medical treatment can 
be initiated (ELLIOTT, 2005). 
 
6.5.2.    Medical management 
Some dogs with primary hyperlipidemia will not sufficiently respond to feeding a low 
or extra low fat diet alone, especially when hypertriglyceridemia is due to 
endogenously formed triglycerides (FORD, 1993; WATSON & BARRIE, 1993; 
BAUER, 1995; FORD, 1996). In these cases, medical treatment is required in 
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addition to the low fat diet in an effort to effectively reduce serum lipid concentrations 
(FORD, 1993; WATSON & BARRIE, 1993). 
 
Polyunsaturated fatty acids of the n-3 series (omega-3 fatty acids) are abundant in 
marine fish (LOGAS et al., 1991). Omega-3 fatty acid supplementation, usually in the 
form of fish-oil, has been shown to lower serum lipoprotein concentrations in humans 
with primary hypertriglyceridemia, normal humans, and experimental animals 
(ILLINGWORTH et al., 1989; SANDERS et al., 1989; FROYLAND et al., 1995; 
FROYLAND et al., 1996; ADAN et al., 1999; STALENHOEF et al., 2000; 
OKUMURA et al., 2002). Proposed mechanisms of action include decreased 
production of VLDL, which contain high concentrations of triglycerides, and 
inhibition of triglyceride synthesis (LEBLANC et al., 2005). In a recent study of 
healthy dogs, fish-oil supplementation led to a significant reduction of serum 
triglyceride concentrations, suggesting that fish oil supplementation could play a role 
in the treatment of primary canine hypertriglyceridemia (LEBLANC et al., 2005). No 
major side effects were observed (LEBLANC et al., 2005). However, studies 
evaluating the efficacy of fish-oil supplementation in dogs with primary 
hyperlipidemia are lacking and clinical experience is limited. Because side effects are 
rarely reported and efficacy of omega-3 fatty acids is likely, it is recommended by 
some authors that fish-oil should be administered to dogs with primary 
hypertriglyceridemia that do not respond to a low fat diet alone (LOGAS et al., 1991; 
BAUER, 1995; JOHNSON, 2005; LEBLANC et al., 2005). Menhaden fish-oil 
capsules have been successfully used at doses ranging from 220 to 330 mg/kg of body 
weight once a day (BAUER, 1995; LEBLANC et al., 2005). Periodic retesting of 
serum triglyceride concentrations is recommended during the treatment period. 
 
Gemfibrozil belongs to the group of fibric acid derivatives, and has been reported to 
reduce serum triglyceride concentrations in both healthy humans and patients with 
hypertriglyceridemia (BHATNAGAR et al., 1992; SPENCER & BARRADELL, 
1996; STALENHOEF et al., 2000). In dogs its use is anecdotal and it is usually 
administered at a fixed dose of 200 mg/day (BAUER, 1995). Because side effects are 
believed to be minimal and occur rarely, gemfibrozil is commonly recommended in 
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combination with dietary therapy when the latter fails to lower serum triglyceride 
concentrations below 500 mg/dL (BAUER, 1995; WHITNEY, 1992). 
 
Niacin is a vitamin that has been used successfully for the treatment of hyperlipidemia 
in humans for many years (KASHYAP et al., 2002). In dogs, niacin treatment has 
been reported in very few patients with primary hypertriglyceridemia. Niacin reduced 
serum triglyceride concentrations in dogs for several months without causing any side 
effects (WHITNEY, 1992; BAUER, 1995; JOHNSON, 2005). However, large clinical 
trials regarding the efficacy and safety of niacin use in dogs with primary 
hypertriglyceridemia are lacking. As in humans, niacin administration in dogs is 
potentially associated with side effects such as erythema and pruritus (BAUER, 1995; 
KASHYAP et al., 2002). Niacin is usually administered at the dose of 25 to 100 
mg/day (BAUER, 1995). 
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1.1.    Abstract 
Background: Idiopathic hypertriglyceridemia has been reported in Miniature 
Schnauzers (MS). However, studies investigating the prevalence of this disorder in a 
large population of MS are lacking.  
Hypothesis: Our hypothesis was that hypertriglyceridemia is prevalent in healthy 
MS.  
Animals: 192 healthy MS and 38 healthy dogs of other breeds (control dogs). 
Methods: Serum triglyceride and cholesterol concentrations were measured and 
statistically compared in both the MS and control group. Dogs were categorized based 
on their age, and median serum triglyceride concentrations were compared among 
different age groups.  
Results: A total of 63 (32.8%) of the 192 MS had serum triglyceride concentrations 
above the reference range. In contrast, of the 38 control dogs, only 2 (5.3%) had 
serum triglyceride concentrations above the reference range. The median serum 
triglyceride concentration in MS was 73.5 mg/dL, which was significantly higher 
compared to that of the control group (median, 55 mg/dL; p=0.0005). Serum 
cholesterol concentration was above the reference range in 9 (9.0%) of 100 MS and in 
2 (5.3%) of the control dogs. Mean serum cholesterol concentrations were not 
significantly different between the 2 groups (p=0.1374). Median serum triglyceride 
concentrations in MS increased significantly with age (p<0.0001), and there was a 
significant positive correlation between serum triglyceride concentrations and age 
(Spearman r=0.47; p<0.0001). There was no difference in serum triglyceride 
concentrations between male and female MS (p=0.48).  
Conclusion: Healthy Miniature Schnauzers have a high prevalence of 
hypertriglyceridemia compared to healthy dogs of other breeds. Both the prevalence 
and severity of hypertriglyceridemia increase with age.  
1.2.    Key words 
Idiopathic, hypercholesterolemia, hyperlipidemia, dog, prevalence, age. 
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1.3.    Introduction 
Hypertriglyceridemia, which refers to abnormally increased serum triglyceride 
concentrations, is a relatively common clinicopathologic finding in dogs.
1
 In a study 
of 1,022 blood samples from both healthy and diseased dogs of various breeds, 5.4% 
had increased serum triglyceride concentrations, but the study did not include grossly 
lipemic samples.
1
 Postprandial hypertriglyceridemia is normal and transient, and 
typically resolves within 7-12 hours after a meal, depending on the fat content of the 
meal.
2,3
 Persistent fasting hypertriglyceridemia is always considered abnormal and 
can either be primary (idiopathic) or secondary to other diseases or drug 
administration.
2
 Secondary hypertriglyceridemia, which is the most common form in 
dogs, usually is the result of an endocrine disorder such as hypothyroidism, diabetes 
mellitus, or hyperadrenocorticism.
4,5
 Other possible causes of secondary 
hypertriglyceridemia include pancreatitis,
6
 obesity,
7,8
 lymphoma,
9
 or administration of 
certain drugs (e.g., glucocorticoids).
10
 A presumptive diagnosis of idiopathic 
hypertriglyceridemia can only be made when other causes of secondary 
hypertriglyceridemia have been ruled out. Idiopathic hypertriglyceridemia appears to 
be associated with specific breeds, most commonly Miniature Schnauzers.
2,11-14
 Other 
breeds, however, as well as mixed breed dogs, also can be affected.
2,15,16
 Dogs with 
severe hypertriglyceridemia might be at increased risk for the development of 
pancreatitis,
2,11,17
 seizures,
11,18
 or both, although the relationship between these 
disorders and hypertriglyceridemia has not been proven. 
 
Idiopathic hypertriglyceridemia has been reported in Miniature Schnauzers in the 
United States, but has not been documented elsewhere.
11-14
 It is characterized by 
abnormal accumulation of very low density lipoproteins (VLDL) or a combination of 
VLDL and chylomicrons.
12,13
 Although hypercholesterolemia may also be present, 
this finding is not consistent.
12-14
 The cause of hypertriglyceridemia in Miniature 
Schnauzers remains unclear, but possible mechanisms include increased production of 
VLDL and chylomicrons, decreased clearance of VLDL and chylomicrons or both. 
The fact that hypertriglyceridemia is prevalent within a single breed suggests a 
possible hereditary mechanism.
11-13
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Although it is generally accepted that idiopathic hypertriglyceridemia is a common 
disorder in Miniature Schnauzers in the United States, and despite the fact that it can 
potentially be associated with serious diseases (e.g., pancreatitis), it has received 
limited attention. The assumption that Miniature Schnauzers have a high incidence of 
primary hypertriglyceridemia compared to other breeds is largely anecdotal or based 
on small case series.
11,13
 Studies investigating the prevalence and clinical implications 
of the disease in large populations of Miniature Schnauzers are lacking. Also, the 
effects of age, sex, and reproductive status on serum triglyceride concentrations have 
not been sufficiently studied in Miniature Schnauzers.  
 
The aim of this study was to determine the prevalence of hypertriglyceridemia in a 
large population of healthy Miniature Schnauzers, and to further characterize this 
condition in this breed.  
1.4.    Materials and Methods 
Serum samples were collected from healthy Miniature Schnauzers (Miniature 
Schnauzer group). A total of 118 Miniature Schnauzer breeders affiliated with the 
American Miniature Schnauzer Club located in the United States were randomly 
selected, contacted by e-mail, and notified about the study. Several other Miniature 
Schnauzer breeders and owners were informed through the breeders initially 
contacted. Dog owners and breeders interested in this study were asked to contact the 
Gastrointestinal Laboratory to have their dogs enrolled. Breeders and owners who 
decided to participate in the study were sent a package containing an ice pack and 
materials necessary for blood collection and were asked to schedule an appointment 
with their veterinarian for blood collection. Veterinarians were instructed to collect 5-
10 ml of blood into a tube containing no additive, centrifuge the sample after clot 
formation, separate the serum from the blood clot, transfer the serum into another 
tube, and send the samples to the Gastrointestinal Laboratory packaged on ice by 
overnight courier. Breeders and owners were instructed not to feed their dogs for at 
least 12 hours before the scheduled blood collection. In addition, they were asked to 
complete a questionnaire for each dog. Information gathered included date of birth, 
sex, reproductive status (i.e., intact or neutered), body weight, current diet(s), current 
medication(s), and current and past health status of the dog. Finally, all breeders and 
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owners signed and returned an informed owner consent form to the Gastrointestinal 
Laboratory.  
 
Upon receipt, serum samples were immediately aliquoted and stored at -80
o
C until 
analysis. Samples were analyzed for serum triglyceride concentration using an 
enzymatic assay.
a
 Samples from some of the Miniature Schnauzers also were 
analyzed for serum cholesterol concentration using an enzymatic assay.
a
 
Questionnaires from all dogs were reviewed. Inclusion criteria consisted of absence of 
clinical signs of any disease for at least 3 months before blood collection, absence of a 
history of chronic diseases that might affect lipid metabolism (e.g., endocrine 
disorders), and absence of current medications that may affect lipid metabolism (e.g., 
glucocorticoids). 
 
A total of 38 healthy dogs served as controls. Of the 38 dogs, 20 were pure bred dogs 
consisting of 12 breeds, and 18 dogs were mixed breed dogs. The breeds in the 
control group included Labrador Retriever (3), Boxer (2), Border Collie (2), Boston 
Terrier (2), Golden Retriever (2), German Shepherd (1), English Mastiff (1), Alaskan 
Malamute (1), Basset Hound (1), Bloodhound (1), Redbone Coonhound (1), 
Weimaraner (1), Blue Lacy (1), Whippet (1) and 18 mixed breed dogs. Due to the fact 
that Beagles have been reported to have a familial form of hyperlipoproteinemia, dogs 
of this breed were not included in this study.
2,16
 Control dogs were owned by students 
and staff of the College of Veterinary Medicine and Biomedical Sciences at Texas 
A&M University. Owners had been asked not to feed their dogs for at least 12 hours 
before blood collection. In addition, owners were asked to fill out a short 
questionnaire similar to the one used for the Miniature Schnauzers and were asked to 
sign an informed owner consent form. Blood samples were collected and, after clot 
formation and centrifugation at 3,000 rpm for 15 min, serum was transferred to a 
separate tube and stored at - 80
o
C until further use. Samples were analyzed for the 
same constituents as were the samples from the Miniature Schnauzers. 
 
For statistical analyses, the total number of Miniature Schnauzers and dogs of the 
control group with serum triglyceride concentrations above the upper limit of the 
reference range were recorded. Also, the total number of Miniature Schnauzers and 
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dogs of the control group with serum cholesterol concentrations above the upper limit 
of the reference range were recorded. For the purposes of this study, Miniature 
Schnauzers were divided into 3 subgroups based on their serum triglyceride 
concentration: Miniature Schnauzers with normal (reference range: 26-108 mg/dL), 
mildly increased (109-400 mg/dL), and moderately to severely increased (>400 
mg/dL) serum triglyceride concentrations. Although generally accepted criteria for 
categorization of the severity of hypertriglyceridemia are not available, a previously 
suggested categorization was used here.
19
 All data were tested for normal distribution 
using the Kolmogorov-Smirnov test. Median serum triglyceride and mean serum 
cholesterol concentrations were compared between the Miniature Schnauzers and the 
control group using a Mann - Whitney test. The proportion of Miniature Schnauzers 
with serum triglyceride concentrations above the upper limit of the reference range 
was compared with the proportion of control dogs with serum triglyceride 
concentrations above the reference range by use of a Fisher’s exact test. Odds ratios 
with their 95% confidence intervals for having an increased serum triglyceride 
concentration also were calculated for the above data.  
 
Miniature Schnauzers and control dogs were categorized by age into 5 subgroups 
(group 1: < 1 year, group 2: 1 to 3 years, group 3: 3 to 6 years, group 4: 6 to 9 years, 
and group 5: > 9 years). The number of Miniature Schnauzers in each age group was: 
26 for group 1, 51 for group 2, 52 for group 3, 23 for group 4, and 30 for group 5; the 
number of control dogs in each age group was: 4 for group 1, 12 for group 2, 11 for 
group 3, 3 for group 4 and 3 for group 5. Comparison of serum triglyceride 
concentrations among the age classes was based on a Kruskal-Wallis test followed by 
a Dunn’s multiple comparison test. The percentages of Miniature Schnauzers and 
control dogs with serum triglyceride concentrations above the upper limit of the 
reference range, as well as above 400 mg/dL, in each age group were recorded. Also, 
to investigate whether a systematic change in serum triglyceride concentrations 
occurred with age, data were analyzed for correlation between serum triglyceride 
concentrations and age in both the Miniature Schnauzers and the control group. A 
Fisher’s exact test was used to determine whether serum triglyceride concentration 
was associated with sex or reproductive status. 
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For analysis of data sets that were normally distributed, unpaired t-tests and one way 
ANOVAs were used. All statistical analyses were performed using a statistical 
software package
b
 and a p value of < 0.05 was considered significant. 
1.5.    Results 
Serum samples were collected from a total of 213 Miniature Schnauzers. Of those, 
192 were suitable (based on their medical history) for enrollment into the study. The 
21 dogs that were not enrolled in the study had clinical signs at the time of blood 
collection or within <3 months before blood collection. Data on sex and reproductive 
status were available for 187 of the 192 dogs; 114 (61%) of these dogs were female 
and 73 (39%) were male. Forty one (36%) females were spayed and 34 (46.6%) males 
were castrated. Age was available for 182 Miniature Schnauzers and the median age 
was 45 months (range, 4-161 months). Of the 38 dogs in the control group, 17 were 
female (1 intact and 16 spayed) and 21 were male (2 intact and 19 castrated). Age was 
available for 33 dogs (5 dogs were rescue dogs of unknown age), and the median age 
was 42.5 months (range, 2-138 months). There was no significant difference between 
the median ages of the Miniature Schnauzer and control groups (p=0.7106).  
 
A total of 63 (32.8%) of the 192 Miniature Schnauzers had serum triglyceride 
concentrations above the upper limit of the reference range. Of the 38 control dogs, 
only 2 (5.3%) had serum triglyceride concentrations above the upper limit of the 
reference range. Forty one (21.3%) of the 192 Miniature Schnauzers had mild 
increases in serum triglyceride concentration (109-400 mg/dL), and 22 (11.5%) had 
moderate to severe increases in serum triglyceride concentrations (>400 mg/dL). 
None of the control dogs had moderately to severely increased serum triglyceride 
concentrations (>400 mg/dL). The odds ratio for Miniature Schnauzers to have serum 
triglyceride concentrations above the upper limit of the reference range when 
compared to the control group was 8.8 (p=0.0003, 95% CI 2.1 – 37.7). 
 
Serum cholesterol concentrations were measured in a total of 100 Miniature 
Schnauzers. Sixty of them had normal serum triglyceride concentrations, 20 had 
mildly increased serum triglyceride concentrations, and 20 had moderately to severely 
increased serum triglyceride concentrations. A total of 9 (9%) Miniature Schnauzers 
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had serum cholesterol concentrations above the upper limit of the reference range 
(reference range, 124-335 mg/dL), but none (0%) of the 60 Miniature Schnauzers 
with normal serum triglyceride concentrations had a serum cholesterol concentration 
above the upper limit of the reference range. Of the 20 Miniature Schnauzers with 
mildly increased serum triglyceride concentrations only 1 (5%) had a serum 
cholesterol concentration above the upper limit of the reference range, whereas of the 
20 Miniature Schnauzers with moderately to severely increased serum triglyceride 
concentrations 8 (40%) had serum cholesterol concentrations above the upper limit of 
the reference range. In the control group, 2 (5.3%) dogs had serum cholesterol 
concentrations above the upper limit of the reference range; one of these dogs also 
had a serum triglyceride concentration above the reference range.  
 
All data sets, except for serum cholesterol concentrations, failed normality testing and 
non-parametric methods were used for further analysis of the data sets. The median 
serum triglyceride concentration in the Miniature Schnauzer group was 73.5 mg/dL 
(range, 24 – 3,125 mg/dL), which was significantly higher than the median serum 
triglyceride concentration of the control group (median, 55 mg/dL; range, 24 – 205 
mg/dL; p=0.0005; Figure 1). Mean serum cholesterol concentration in Miniature 
Schnauzers was 214 mg/dL, which was not significantly different from the mean 
serum triglyceride concentration in the control group (mean, 233 mg/dL; p=0.1374; 
Figure 2). However, one-way ANOVA analysis showed that the mean serum 
cholesterol concentration in the 20 Miniature Schnauzers with moderately to severely 
increased serum triglyceride concentrations was significantly higher than the mean 
serum cholesterol concentration in the 60 Miniature Schnauzers with normal serum 
triglyceride concentrations (p<0.001) and that of the control group (p<0.001); 
differences between the 20 Miniature Schnauzers with moderately to severely 
increased serum triglyceride concentrations and the 20 Miniature Schnauzers with 
mildly increased serum triglyceride concentrations were not significant (Figure 3).  
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Figure 1. Distribution of serum triglyceride concentrations. 
Scatter plot showing the distribution of serum triglyceride concentrations in Miniature 
Schnauzers and in a group of dogs of other breeds. The line represents the median of 
each group (p=0.0005). 
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Figure 2. Distribution of serum cholesterol concentrations. 
Scatter plot showing the distribution of serum cholesterol concentrations in Miniature 
Schnauzers and in a group of dogs of other breeds. The line represents the mean of 
each group (p=0.1374). 
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Figure 3. Differences in serum cholesterol concentrations among groups. 
Boxplots of serum cholesterol concentrations (mg/dL) for different triglyceride (TG) 
groups in Miniature Schnauzers. The line in the rectangle corresponds to the mean, 
the upper and lower limits of the rectangle correspond to the 25
th
 and 75
th
 percentile, 
respectively, and the whiskers correspond to the lowest and highest values. The p-
values show the significance of the differences in serum cholesterol concentrations 
between groups compared to the group with severely increased serum triglyceride 
concentrations (Severe TG). 
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The Kruskal-Wallis test indicated that median serum triglyceride concentrations in 
Miniature Schnauzers differed significantly among the age classes (p<0.0001; Figure 
4). In particular, median serum triglyceride concentrations of Miniature Schnauzers in 
the age class > 9 years differed significantly from the age classes of < 1 year 
(p<0.001), 1 to 3 years (p<0.001), and 3 to 6 years (p<0.001). In addition, median 
serum triglyceride concentrations of Miniature Schnauzers in the age class < 1 year 
differed significantly from the age class 6 – 9 years (Figure 4). Also, the percentages 
of Miniature Schnauzers with serum triglyceride concentrations above the reference 
range appeared to increase with age (Figure 5). Only 15.4% of dogs < 1 year of age 
and 15.7% of dogs 1 to 3 years of age had serum triglyceride concentrations above the 
reference range, whereas 43.5% of dogs 6 to 9 years of age and 76.7% of dogs > 9 
years of age did. In addition, there appeared to be an association between the degree 
of hypertriglyceridemia and age. Only 3.9% and 3.8% of dogs 1 to 3 and 3 to 6 years 
of age, respectively, had serum triglyceride concentrations > 400 mg/dL, whereas 
17.4% of dogs 6 to 9 years of age and 46.7% of dogs > 9 years of age did (Figure 6). 
Also, 18 of 22 (81.8%) Miniature Schnauzers with moderate to severe 
hypertriglyceridemia were ≥ 6 years of age, and 14 (63.6%) were ≥ 9 years of age. 
There was a significant positive correlation between serum triglyceride concentration 
and age in Miniature Schnauzers (p<0.0001, Spearman r =0.47). The Kruskal-Wallis 
test did not identify significant differences of median serum triglyceride 
concentrations among the age classes in the control group (p=0.2235). There was no 
significant correlation between serum triglyceride concentration and age in the control 
dogs (p=0.6697; Spearman r= -0.077). 
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Figure 4. Serum triglyceride concentrations in different age groups in Miniature 
Schnauzers. 
Boxplots of serum triglyceride concentrations (mg/dL) for different age groups in 
Miniature Schnauzers. The line in the rectangle corresponds to the median, the upper 
and lower limits of the rectangle correspond to the 25
th
 and 75
th
 percentile, 
respectively, and the whiskers correspond to the lowest and highest values. The p-
values show the significance of the differences in serum triglyceride concentrations 
among age groups (Note: the Y-axis is split). 
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Figure 5. Percentages of healthy Miniature Schnauzers with 
hypertriglyceridemia in different age groups. 
Percentages of healthy Miniature Schnauzers with hypertriglyceridemia (serum 
triglyceride concentrations > 108 mg/dL) in different age groups. 
Publications 
 48 
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
40.00%
45.00%
50.00%
<1 1-3 3-6 6-9 >9 
Age groups (years)
P
er
ce
n
ta
g
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Percentages of healthy Miniature Schnauzers with moderate to severe 
hypertriglyceridemia in different age groups. 
Percentages of Miniature Schnauzers with moderate to severe hypertriglyceridemia 
(triglycerides > 400 mg/dL) in different age groups. 
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There was no difference in proportions of Miniature Schnauzers with serum 
triglyceride concentrations above the upper limit of the reference range (p = 0.48) or 
in median serum triglyceride concentrations (p = 0.46) between male and female 
Miniature Schnauzers. There were significant differences in the proportions of 
Miniature Schnauzers with serum triglyceride concentrations above the upper limit of 
the reference range between spayed and intact females (p<0.0001) and between 
castrated and intact males (p = 0.0166). However, there were significant differences in 
median ages between these groups (spayed and intact females: p<0.0001; castrated 
and intact males: p = 0.0248), with neutered animals being older than the intact ones. 
1.6.    Discussion 
Based on the results of the present study, it can be concluded that 
hypertriglyceridemia is a common finding in healthy Miniature Schnauzers in the 
United States, because about one-third of the enrolled Miniature Schnauzers had 
serum triglyceride concentrations above the upper limit of the reference range. Also, 
11.5% of the Miniature Schnauzers in this study had moderate to severe 
hypertriglyceridemia which, based on some authors, is more likely to be associated 
with complications such as pancreatitis or seizures.
12
 Hypertriglyceridemia does not 
appear to be a common finding in healthy dogs of other breeds. In addition, healthy 
control dogs had only mild increases in serum triglyceride concentrations if they had a 
serum triglyceride concentration above the upper limit of the reference range. 
 
Miniature Schnauzers enrolled in this study came from many different locations 
within the United States, thus minimizing the possibility of selection of populations 
that were more inbred than the general Miniature Schnauzer population. Thus, 
findings of this study are believed to reflect the general population of Miniature 
Schnauzers in the United States. 
 
Although the possibility that hypertriglyceridemia in some of the Miniature 
Schnauzers in the present study might have been the result of secondary causes (e.g., 
hyperadrenocorticism) cannot be excluded, we feel that this explanation is unlikely 
because all dogs were free of clinical signs for at least 3 months before blood 
collection, had no known chronic diseases, and were not receiving any medications 
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that are known to or suspected to affect serum triglyceride concentrations. In addition, 
dogs of the control group, which were enrolled based on the same inclusion criteria, 
had a significantly lower prevalence of hypertriglyceridemia. 
 
Information regarding each dog’s current diet (as well as the length of time each dog 
had received that diet) was available for the majority of the dogs in this study. 
However, many dogs were on home made or multiple diets, and it was not possible to 
determine the lipid content of these diets. It is possible that some Miniature 
Schnauzers with normal serum triglyceride concentrations were on low fat diets, and 
that the true percentage of Miniature Schnauzers with hypertriglyceridemia is even 
higher than reported here. Information regarding the body condition score of each dog 
would have been interesting because obesity might affect serum triglyceride 
concentrations,
7
 but this information was not available in the present study. 
 
Most of the affected Miniature Schnauzers had mildly increased serum triglyceride 
concentrations, but a considerable percentage (11.5%) had moderate to severely 
increased serum triglyceride concentrations. As mentioned earlier, dogs with severe 
hypertriglyceridemia might be at increased risk for the development of 
pancreatitis,
2,11,17
 seizures,
11,18
 or both, although the relationship between these 
disorders has not been proven. In addition, because hypertriglyceridemia is a common 
feature of other (mostly endocrine) diseases, the findings of this study are important to 
veterinarians who may be evaluating hypertriglyceridemia in Miniature Schnauzers. A 
large proportion of healthy Miniature Schnauzers have mild, moderate, or even severe 
increases in serum triglyceride concentrations, and further investigation of 
hypertriglyceridemia (e.g., ACTH stimulation test, low dose dexamethasone 
suppression test, determination of serum thyroid hormone concentration) may not be 
indicated in the absence of compatible clinical and clinicopathological findings in 
Miniature Schnauzer dogs.  
 
There currently is no evidence to support the hypothesis that the source (rather than 
the severity) of hypertriglyceridemia can affect the risk for developing secondary 
disorders. It also should be noted that if the severity of hypertriglyceridemia correlates 
with the potential for developing complications secondary to hypertriglyceridemia, 
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Miniature Schnauzers that have idiopathic hypertriglyceridemia might be at even 
higher risk for developing complications of hypertriglyceridemia if they develop 
diseases that lead to secondary hypertriglyceridemia (e.g., diabetes mellitus) as this 
occurrence would potentially lead to additional increases in serum triglyceride 
concentrations.  
 
In Miniature Schnauzers, serum cholesterol concentrations above the upper limit of 
the reference range were noted only in association with moderate to severe 
hypertriglyceridemia and, in 1 dog, with mild hypertriglyceridemia. None of the 
Miniature Schnauzers with normal serum triglyceride concentrations had serum 
cholesterol concentrations above the upper limit of the reference range. Also, many 
Miniature Schnauzers with hypertriglyceridemia had normal serum cholesterol 
concentrations. These findings indicate that hypercholesterolemia is variably present 
in Miniature Schnauzers with hypertriglyceridemia. Hypercholesterolemia may be a 
secondary feature that accompanies moderate to severe hypertriglyceridemia in 
Miniature Schnauzers resulting from decreased clearance, increased production, or 
both, of chylomicrons and VLDL because these 2 molecules also contain small 
amounts of free and esterified cholesterol.
2
 
 
Both the percentages of Miniature Schnauzers with hypertriglyceridemia and the 
degree of hypertriglyceridemia increased with age. More than 75% of Miniature 
Schnauzers ≥ 9 years of age had increased serum triglyceride concentrations, and the 
vast majority (>80%) of Miniature Schnauzers with moderate to severe 
hypertriglyceridemia were 6 years or older. This observation suggests that later 
development of hypertriglyceridemia cannot be excluded in young Miniature 
Schnauzer dogs found to have normal serum triglyceride concentrations. A genetic 
marker may help identify affected dogs before development of hypertriglyceridemia. 
However, although not very common, some young dogs may present with 
hypertriglyceridemia. 
 
Due to the fact that only 1 serum sample was obtained from each dog in the present 
study, it was not possible to determine whether idiopathic hypertriglyceridemia is 
consistently present in affected Miniature Schnauzers. However, in the authors’ 
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experience and based on a few published cases,
13
 most affected Miniature Schnauzers 
remain hypertriglyceridemic throughout their lives unless low fat diets are fed 
consistently. In order to better understand the evolution of serum triglyceride 
concentrations in aging Miniature Schnauzers, further studies in selected groups of 
Miniature Schnauzers are required.  
 
The almost even distribution of hypertriglyceridemia between male and female 
Miniature Schnauzers in the present study suggests that idiopathic 
hypertriglyceridemia is not a sex-linked disorder. X-linked inheritance would lead to 
many more affected males than females, whereas Y-linked inheritance would produce 
only affected males. However, such is not the case for idiopathic hypertriglyceridemia 
in this study. Although significant differences in serum triglyceride concentrations 
were detected between neutered and intact animals, this finding seems to be the result 
of age differences between the 2 groups. 
 
In human medicine, hereditary causes of hypertriglyceridemia are well documented.
20
 
Familial hypertriglyceridemia (transmitted as an autosomal dominant disorder of 
unknown etiology), lipoprotein lipase deficiency (transmitted as an autosomal 
recessive disorder), and familial apolipoprotein C-II deficiency (transmitted as an 
autosomal recessive disorder) are disorders with a genetic basis that all lead to 
increases in serum triglyceride concentrations due to increased concentrations of 
VLDL, chylomicrons, or both.
20
 Hypertriglyceridemia in human beings often is 
asymptomatic but also has been associated with coronary heart disease, pancreatitis, 
non-alcoholic hepatic lipidosis, and metabolic syndrome.
20
  
 
The cause of idiopathic hypertriglyceridemia in Miniature Schnauzers has not yet 
been identified. Regardless of the mechanism, an underlying genetic defect is 
suspected.
11-13
 Because lipoprotein lipase is the major enzyme involved in triglyceride 
clearance, deficiency of this enzyme has been considered a possible cause of 
hypertriglyceridemia. Two studies that included both Miniature Schnauzers and dogs 
of other breeds with idiopathic hyperlipidemia found that lipoprotein lipase activity 
was significantly reduced in hyperlipidemic dogs compared to healthy controls.
c,d
 
However, a recent study in Miniature Schnauzers with hypertriglyceridemia and 
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pancreatitis failed to identify any mutations of the lipoprotein lipase gene, suggesting 
that inherited lipoprotein lipase dysfunction may not be the cause of 
hypertriglyceridemia in this breed.
e
 Further studies are warranted in order to identify 
the genetic basis of idiopathic hypertriglyceridemia in Miniature Schnauzers. 
 
In conclusion, results of the present study suggest that idiopathic hypertriglyceridemia 
is a common finding in healthy Miniature Schnauzers in the United States. There is no 
difference between male and female Miniature Schnauzers with regard to the 
prevalence of hypertriglyceridemia. Both the prevalence and severity of 
hypertriglyceridemia in Miniature Schnauzers increase with age. Due to the high 
prevalence of this disorder in Miniature Schnauzers, extensive diagnostic work-up in 
order to identify the cause of hypertriglyceridemia probably is not necessary in 
otherwise healthy Miniature Schnauzer dogs. However, on the basis of the results of 
the present study, all Miniature Schnauzers in the United States should potentially be 
evaluated for hypertriglyceridemia while they are healthy, because this information 
may be useful for the avoidance of misinterpretation of increased serum triglyceride 
concentrations when the dogs are presented sick. In addition, by knowing the serum 
triglyceride status of the dog, veterinarians might consider offering low fat diets to 
affected dogs in order to avoid possible complications of hypertriglyceridemia. Due to 
the fact that hypercholesterolemia was found only in association with 
hypertriglyceridemia, the presence of hypercholesterolemia alone in Miniature 
Schnauzers might require additional diagnostic investigation. Genetic studies are 
warranted in order to obtain further information about the genetic basis of this 
disorder. In addition, the association between hypertriglyceridemia and diseases such 
as pancreatitis and seizures remains to be determined. 
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1.7.    Footnotes
 
a
Roche/Hitachi MODULAR ANALYTICS D 2400 module, Roche Diagnostics, 
Indianapolis, IN 
b
Prism4, GraphPad, San Diego, CA
 
c
Schenck PA. Lipoprotein lipase and hepatic lipase activity in dogs with primary 
hyperlipoproteinemia. J Vet Int Med 2002, 17:386 (abstract) 
d
Jaeger JQ, Jonson S, Hinchcliff KW, Sherding R, Jensen W, Brunzell J, Murdock S. 
Characterization of biochemical abnormalities in idiopathic hyperlipidemia of 
Miniature Schnauzer dogs. J Vet Int Med 2003, 16:394 (abstract) 
e
Schickel R. Identification of the nucleotide sequence of the lipoprotein lipase gene as 
well as its role in the developmet of hyperlipidemia and pancreatitis in the Miniature 
Schnauzer. 2005. Ludwig-Maximilians University (Dr.med.vet. thesis) 
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2.1.    Abstract 
Objective—To determine whether hypertriglyceridemia in healthy Miniature 
Schnauzers was associated with high serum liver enzyme activities. 
Design—Cross-sectional study. 
Animals—65 Miniature Schnauzers with normal serum triglyceride concentrations 
(group 1), 20 Miniature Schnauzers with slightly high serum triglyceride 
concentrations (group 2), and 20 Miniature Schnauzers with moderately to severely 
high serum triglyceride concentrations (group 3).  
Procedures—Questionnaires regarding each dog’s medical history were completed, 
and serum alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), and γ-glutamyltransferase (GGT) activities were measured. 
Results—Median serum ALP activity was significantly higher in group 3 than in 
group 1 or 2 dogs, but was not significantly higher in group 2 than in group 1 dogs. 
Median serum ALT activity was significantly higher in group 3 than in group 1 dogs, 
but was not significantly different between any of the other groups. Compared with 
group 1 dogs, group 2 and 3 dogs were significantly more likely to have high serum 
ALP activity (odds ratio, 26.2 and 192.6, respectively). Group 3 dogs also were 
significantly more likely to have high serum ALT activity (odds ratio, 8.0), serum 
AST activity (odds ratio, 3.7), and serum GGT activity (odds ratio, 11.3), compared 
with group 1 dogs. Group 3 dogs were significantly more likely (odds ratio, 31.0) to 
have ≥ 2 high serum liver enzyme activities than were group 1 dogs.  
Conclusions and Clinical Relevance—Results suggested that moderate to severe 
hypertriglyceridemia was associated with high serum liver enzyme activities in 
Miniature Schnauzers. 
2.2.    Abbreviations 
VLDL  Very low density lipoproteins 
NAFLD Nonalcoholic fatty liver disease 
ALP  Alkaline phosphatase 
ALT  Alanine aminotransferase 
AST  Aspartate aminotransferase 
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GGT  γ-Glutamyltransferase 
2.3.    Introduction  
Persistent hypertriglyceridemia is reportedly common in healthy Miniature 
Schnauzers in the United States,
1-4
 with hypertriglyceridemia identified in 63 of 192 
(32.8%) healthy Miniature Schnauzers in 1 study.
4
 Hypertriglyceridemia in Miniature 
Schnauzers is characterized by an abnormal accumulation of VLDL or a combination 
of VLDL and chylomicrons, with or without hypercholesterolemia.
2,3
 The cause of 
this condition remains unclear, but possible mechanisms include increased production 
or decreased clearance of VLDL and chylomicrons.
2
 Dogs with severe 
hypertriglyceridemia have been suspected to be at increased risk for development of 
pancreatitis
1,5-8
 and seizures,
1,9
 although a relationship between hypertriglyceridemia 
and these disorders has not been proven. 
 
In human beings, hypertriglyceridemia has been associated with development of fatty 
liver and a condition known as NAFLD.
10-14
 This condition is characterized by 
excessive lipid deposition in the hepatocytes with or without concurrent 
inflammation, fibrosis, and cirrhosis in the absence of alcohol abuse.
10
 The 
pathogenesis of fatty liver and NAFLD is not completely understood but is believed 
to involve several factors, including hypertriglyceridemia, that can potentially lead to 
substantial lipid deposition in hepatocytes.
10,11
 The prevalence of fatty liver in patients 
with hyperlipidemia, including both hypertriglyceridemia and hypercholesterolemia, 
has been reported to be about 50%.
12,14
 However, hypertriglyceridemia has been 
found to be a more useful predictor of fatty liver and, in 1 study,
12
 about 70% of 
patients with hypertriglyceridemia were found to have ultrasonographic evidence of 
fatty infiltration of the liver or NAFLD. Most human patients with NAFLD remain 
asymptomatic for long periods, and many of these patients have only abnormally high 
liver enzyme activities as the initial manifestation of NAFLD.
10-12
 Liver enzyme 
activities are usually only mildly high (ie, < 2 times the upper reference limit), with 
high values typically identified during routine screening.
10,11
 To the authors’ 
knowledge, studies investigating a possible association between hypertriglyceridemia, 
high serum liver enzyme activities, and liver disease in dogs have not been described.  
Publications 
 60 
 
Our hypothesis was that hypertriglyceridemia in overtly healthy Miniature Schnauzers 
might be associated with high serum liver enzyme activities. Thus, the purpose of the 
study reported here was to determine whether hypertriglyceridemia in healthy 
Miniature Schnauzers was associated with high serum liver enzyme activities. 
Specifically, we wanted to determine whether serum liver enzyme activities in 
Miniature Schnauzers with hypertriglyceridemia were significantly different from 
activities in Miniature Schnauzers with normal serum triglyceride concentrations. 
2.4.    Materials and Methods 
Serum samples from 105 healthy Miniature Schnauzers were used in the study. All 
samples had been collected as part of a separate study
4
 of healthy Miniature 
Schnauzers from various parts of the United States. Breeders and owners who had 
agreed to participate in the previous study were sent a package containing an ice pack 
and materials necessary for blood collection and were asked to schedule an 
appointment with their veterinarian for blood collection. Veterinarians were instructed 
to collect 5 to 10 mL of blood and to submit serum samples on ice to the 
Gastrointestinal Laboratory at Texas A&M University by overnight courier. Breeders 
and owners were instructed not to feed their dogs for at least 12 hours before blood 
samples were collected. In addition, they were asked to complete a questionnaire for 
each dog that requested information regarding date of birth, sex, neuter status, body 
weight, current diet, current medications, and current and past health status of the dog. 
Finally, all breeders and owners were requested to sign and return an informed 
consent form.  
 
On receipt, serum samples were immediately divided into aliquots and stored at -80
o
C 
until analyzed. Serum triglyceride concentration was measured with an enzymatic 
assay,
4,a
 and serum ALT, AST, ALP, and GGT activities were measured by means of 
spectrophotometric methods with automated equipment.
b
 Questionnaires were 
reviewed, and dogs were included in the study only if they had not had any clinical 
signs of disease for at least 3 months prior to blood collection, did not have any 
history of chronic diseases that might affect lipid metabolism (eg, endocrine 
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disorders), did not have any history of liver disease, and were not currently receiving 
any medications that may affect lipid metabolism or liver enzyme activities. 
 
For purposes of the present study, Miniature Schnauzers were divided into 3 groups 
on the basis of serum triglyceride concentration. Group 1 consisted of 65 Miniature 
Schnauzers in which serum triglyceride concentration was within reference limits (26 
to 108 mg/dL), group 2 consisted of 20 Miniature Schnauzers in which serum 
triglyceride concentration was slightly high (109 to 400 mg/dL), and group 3 
consisted of 20 Miniature Schnauzers in which serum triglyceride concentration was 
moderately to severely high (> 400 mg/dL). Because liver enzyme activities might 
increase with age, a subgroup of group 1 (group 1B) was created that consisted of 26 
dogs that were ≥ 5 years old so that median age of group 1B dogs was similar to 
median age for group 3 dogs.  
 
Of the 65 dogs in group 1, 43 were female (16 spayed), and 21 were male (8 
castrated); sex of 1 dog was not reported. Twelve group 2 dogs were female (7 
spayed), and 8 were male (5 castrated), and 13 group 3 dogs were female (12 spayed), 
and 7 were male (5 castrated). Sixteen of the group 1B dogs were female (8 spayed), 
and 10 were male (4 castrated). 
 
Because lipemia reportedly can interfere with certain serologic assays, resulting in 
falsely high or low results, 8 lipemic samples from group 3 dogs were tested for 
serum triglyceride concentrations and liver enzyme activities before and after 
centrifugation at 20,000 × g for 15 minutes. 
 
Statistical analysis—Data were tested for normal distribution by use of the 
Kolmogorov-Smirnov test. Because data were not normally distributed, the Kruskal-
Wallis test followed by the Dunn multiple comparison procedure was used to compare 
median age and median serum ALP, ALT, AST, and GGT activities among groups. 
Proportions of dogs in each group with serum ALP, ALT, AST, or GGT activities 
greater than the upper reference limit were compared among groups by use of the 
Fisher’s exact test. Similarly, the Fisher’s exact test was used to compare proportions 
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of dogs with ≥ 2 serum liver enzyme activities greater than the upper reference limit 
among groups. Odds ratios and their 95% confidence intervals (CI) were calculated 
for proportions of dogs with serum liver enzyme activities greater than the upper 
reference limit. To determine whether a systematic change in serum liver enzyme 
activities occurred with increasing serum triglyceride concentrations, data were 
analyzed for correlations between serum activity of each enzyme and serum 
triglyceride concentrations by means of the Spearman correlation. Finally, paired t 
tests were used to analyze serum liver enzyme activities obtained for the 8 lipemic 
samples before and after centrifugation. All statistical analyses were performed with 
standard statistical software.
c
 Values of P < 0.05 were considered significant. 
2.5.    Results 
For the 8 lipemic samples, no significant differences were found between mean ALP 
(P = 0.444), ALT (P = 0.882), AST (P = 0.101), and GGT (P = 0.509) activities 
obtained before and after centrifugation.  
 
Median serum triglyceride concentration was 60 mg/dL (range, 24 to 105 mg/dL) for 
dogs in group 1, 247 mg/dL (range, 113 to 380 mg/dL) for dogs in group 2, 690 
mg/dL (range, 423 to 3,125 mg/dL) for dogs in group 3, and 72 mg/dL (range, 30 to 
100 mg/dL) for dogs in group 1B. Median age was 51 months (range, 7 to 151 
months) for dogs in group 1, 70 months (range, 8 to 151 months) for dogs in group 2, 
112 months (range, 18 to 161 months) for dogs in group 3, and 88 months (range, 61 
to 151 months) for dogs in group 1B. There was no significant difference in median 
age between groups 1 and 2, but there was a significant (P < 0.001) difference in 
median age between groups 1 and 3. Median age for group 1B was not significantly 
(P = 0.071) different from median age for group 3. 
 
Median serum ALP activity was significantly higher in group 3 dogs (202.5 U/L) than 
in group 1 dogs (27 U/L; P < 0.001), group 1B dogs (36 U/L; P < 0.001), or group 2 
dogs (33 U/L; P < 0.05), but was not significantly higher in group 2 dogs than in 
group 1 dogs (Figure 1). Median serum ALT activity was significantly higher in 
group 3 dogs (70.5 U/L) than in group 1 dogs (43 U/L; P < 0.01), but was not 
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significantly different between any of the other groups (Figure 2). No significant 
differences were found in median serum AST and GGT activities between any of the 
groups. 
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Figure 1—Serum ALP activities in healthy Miniature Schnauzers. 
Scatterplots of serum ALP activities in 65 healthy Miniature Schnauzers with normal 
serum triglyceride concentrations (group 1), 20 healthy Miniature Schnauzers with 
slightly high serum triglyceride concentrations (group 2), and 20 healthy Miniature 
Schnauzers with moderately to severely high serum triglyceride concentrations (group 
3). Values for a subset of group 1 dogs ≥ 5 years old (group 1B) are also shown. For 
each group, the solid horizontal line represents the median; the horizontal dashed line 
represents the upper reference limit (122 U/L). 
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Figure 2— Serum ALT activities in healthy Miniature Schnauzers. 
Scatterplots of serum ALT activities in healthy Miniature Schnauzers. See Figure 1 
for key. 
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Proportions of dogs with serum liver enzyme activities greater than the upper 
reference limit were substantially higher for group 3 than for group 1 (Table 1). 
Compared with group 1 dogs, group 2 and group 3 dogs were significantly more 
likely to have high serum ALP activity (ie, serum ALP activity greater than the upper 
reference limit; odds ratio, 26.2 and 192.6, respectively; Table 2). Group 3 dogs also 
were significantly more likely to have high serum ALT activity (odds ratio, 8.0), 
serum AST activity (odds ratio, 3.7), and serum GGT activity (odds ratio, 11.3), 
compared with group 1 dogs. Group 3 dogs were significantly more likely (odds ratio, 
31.0) to have ≥ 2 high serum liver enzyme activities than were group 1 dogs. 
Compared with group 1B dogs, dogs in group 3 were significantly more likely to have 
high serum ALP activity (odds ratio, 77.9), serum ALT activity (odds ratio, 6.3), and 
serum AST activity (odds ratio, 5.1) and to have ≥ 2 high serum liver enzyme 
activities (odds ratio, 37.5). 
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Table 1—Proportions of healthy Miniature Schnauzers with and without 
hypertriglyceridemia that had high serum liver enzyme activities. 
 
 Group ALP ALT AST GGT ≥ 2 high enzyme activities 
1 (n = 65) 0 (0) 6 (9) 10 (15) 1 (2) 3 (5) 
1B (n = 26) 0 (0) 3 (12) 3 (12) 1 (4) 1 (4) 
2 (n = 20) 3 (15) 3 (15) 2 (10) 1 (5) 3 (15) 
3 (n = 20) 12 (60) 9 (45) 8 (40) 3 (15) 12 (60) 
 
Data are given as number (%) of dogs with high activities (ie, activities greater than 
the upper reference limit) and represent values for 65 healthy Miniature Schnauzers 
with normal serum triglyceride concentrations (group 1), 20 healthy Miniature 
Schnauzers with slightly high serum triglyceride concentrations (group 2), 20 healthy 
Miniature Schnauzers with moderately to severely high serum triglyceride 
concentrations (group 3), and a subset of group 1 dogs that were ≥ 5 years old (group 
1B).
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Table 2—Likelihood of high serum liver enzyme activities in healthy Miniature Schnauzers with and without hypertriglyceridemia. 
 
 Group 2 vs group 1 Group 3 vs group 1 Group 3 vs group 1B 
Variable OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value 
ALP 26.2 (1.3–531.8) 0.012 192.6 (10.4–3,559) < 0.001 77.9 (4.2–1,461) < 0.001 
ALT 1.7 (0.4–7.7) 0.434 8.0 (2.4–27.2) < 0.001 6.3 (1.4–27.9) 0.017 
AST 0.6 (0.12–3.1) 0.723 3.7 (1.2–11.2) 0.028 5.1 (1.1–22.9) 0.038 
GGT 3.4 (0.2–56.5) 0.417 11.3 (1.1–115.6) 0.039 4.4 (0.4–46.1) 0.303 
≥ 2 high enzyme activities 3.6 (0.7–19.7) 0.139 31 (17.2–134) < 0.001 37.5 (14.2–335.2) < 0.001 
 
See Table 1 for group designations. 
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There was a significant positive correlation between serum ALP activity and serum 
triglyceride concentration (r = 0.53; P < 0.001) and between serum ALT activity and 
serum triglyceride concentration (r = 0.29; P = 0.003). In contrast, serum AST (r = 
0.17; P = 0.236) and GGT activities (r = –0.17; P = 0.085) were not significantly 
correlated with serum triglyceride concentration. 
2.6.    Discussion 
Results of the present study indicated that moderate to severe hypertriglyceridemia 
(ie, serum triglyceride concentration > 400 mg/dL) was associated with high serum 
liver enzyme activities in Miniature Schnauzers. Although significant associations 
between moderate to severe hypertriglyceridemia and high serum liver enzyme 
activities were found for all enzymes studied, the most profound association involved 
serum ALP activity, in that Miniature Schnauzers with moderate to severe 
hypertriglyceridemia were 192.6 times more likely to have a high serum ALP activity 
than Miniature Schnauzers with normal serum triglyceride concentration. In addition, 
Miniature Schnauzers with moderate to severe hypertriglyceridemia were 31 times as 
likely to have ≥ 2 high serum enzyme activities as were Miniature Schnauzers with 
normal serum triglyceride concentration. 
 
There was a significant difference in median ages of dogs in groups 1 and 3 in the 
present study. Because liver enzyme activities might increase with age as a result of 
benign conditions of the liver that tend to occur in older animals (eg, nodular 
hyperplasia),
15
 this difference in age between groups could potentially have biased our 
results. However, when only those dogs in group 1 that were ≥ 5 years old (ie, group 
1B dogs) were compared with group 3 dogs, similar associations between moderate to 
severe hypertriglyceridemia and serum liver enzyme activities were still found.  
 
The etiology of high serum liver enzyme activities in Miniature Schnauzers with 
hypertriglyceridemia was not determined in the present study. In human beings, 
hypertriglyceridemia has been associated with fatty infiltration of the liver and 
asymptomatic increases in serum liver enzyme activities.
10,12,16
 In these patients, 
increases in serum liver enzyme activities are usually mild and involve various 
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combinations of increases in ALT, AST, ALP, and GGT activity.
10,12
 Although high 
serum ALT activities seem to be more commonly reported in human patients with 
fatty liver or NAFLD, high serum ALP activity is also very common, and a recent 
study
17
 in humans showed that a subset of patients with histopathologically confirmed 
NAFLD, regardless of etiology, have only high serum ALP activity. It is not known 
whether high serum liver enzyme activities in Miniature Schnauzers in the present 
study with hypertriglyceridemia were associated with fatty infiltration of the liver, but 
this is quite likely. The fact that serum ALP activity, and not serum ALT activity, had 
the strongest association with hypertriglyceridemia in the present study may suggest 
that the underlying liver condition in Miniature Schnauzers with hypertriglyceridemia 
differs from NAFLD in humans.  
 
Alkaline phosphatase is a membrane-bound enzyme, and its activity increases in 
serum as a result of increased enzyme production stimulated by impaired bile flow or 
various drugs.
18
 Fatty infiltration of the liver can potentially lead to cholestasis and 
increases in serum ALP and, to a lesser degree, GGT activities.
18
 In contrast, ALT and 
AST are cytosolic enzymes that leak from hepatocytes following injury and altered 
permeability of the hepatocellular membrane.
18
 Hepatocellular injury following fatty 
infiltration and inflammation of the liver might explain increases of these enzyme 
activities in Miniature Schnauzers with hypertriglyceridemia. 
 
The pathogenesis of fatty liver and NAFLD in hypertriglyceridemic human patients 
remains uncertain.
10
 However, insulin resistance and hyperinsulinemia are believed to 
play a key role in the pathogenesis of NAFLD,
10
 and it has been reported that in 
humans, hypertriglyceridemia is associated with insulin resistance and 
hyperinsulinemia.
19
 In dogs, any association between hypertriglyceridemia and 
resistance to insulin remains to be determined. 
 
Anecdotal observations suggest that 2 conditions of the liver might be associated with 
hypertriglyceridemia in Miniature Schnauzers: vacuolar hepatopathy and gallbladder 
mucocele.
20,21
 The first shares some common characteristics with NAFLD, such as the 
fact that both can be subclinical for long periods and that histologically they are 
characterized by vacuole formation within hepatocytes.
11,21,22
 Gallbladder mucocele 
has been commonly reported in dog breeds that are predisposed to idiopathic 
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hyperlipidemia, such as Miniature Schnauzers and Shetland Sheepdogs, and has also 
been described in humans with hypelipidemia.
23-25
 However, a clear association 
between the presence of hyperlipidemia and gallbladder mucocele formation has not 
been identified in dogs. In a recent study,
24
 an association between gallbladder 
mucocele formation and dyslipidemias (hypertriglyceridemia and 
hypercholesterolemia) in Shetland Sheepdogs was described. In that study,
24
 many of 
the dogs with gallbladder mucocele were found to have no clinical signs or 
biochemical abnormalities, except for high serum ALP activity in some cases. 
Whether this could explain the high serum liver enzyme activities in Miniature 
Schnauzers with hypertriglyceridemia remains to be determined. Further studies 
involving histologic and ultrasonographic examination of the liver are underway in an 
attempt to identify concurrent liver diseases in Miniature Schnauzers with 
hypertriglyceridemia. 
 
The possibility that high serum liver enzyme activities, especially high ALP and AST 
activities, in dogs with hypertriglyceridemia in the present study were a result of 
extrahepatic diseases (eg, hyperadrenocorticism) cannot be excluded, because 
diagnostic tests to exclude other diseases were not performed. However, this 
possibility seems unlikely, in that all dogs were free from clinical signs for at least 3 
months prior to blood collection and did not have any history of chronic diseases that 
might affect serum liver enzyme activities. In addition, serum activity of ALT, which 
is considered specific to the liver, was high in many of the dogs with 
hypertriglyceridemia, which would suggest that these dogs had a primary hepatic 
process. It is of interest that when serum cholesterol concentrations, which have been 
reported to be high in 90% of all dogs with hyperadrenocorticism,
26
 were measured in 
the 40 Miniature Schnauzers in the present study with hypertriglyceridemia, only 9 
(23%) were found to have high serum cholesterol concentrations.
4
 Thus, it seems 
unlikely that underlying hyperadrenocorticism played a role in the high serum ALP 
activities among Miniature Schnauzers with hypertriglyceridemia in the present study. 
In addition, dogs were not receiving any medications known to affect serum liver 
enzyme activities.  
 
Similarly, although there have been concerns that lipemia may have affected serum 
liver enzyme values, the fact that we found no significant differences in mean ALP, 
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ALT, AST, or GGT activities before and after centrifugation for 8 samples with 
lipemia suggested that lipemia did not substantially interfere with assays used to 
measure serum liver enzyme activities in the present study. 
 
It is not known how long hypertriglyceridemia must be present before serum liver 
enzyme activities will start to increase. Also, it is unknown whether increases in 
serum liver enzyme activities are persistent or whether correction of 
hypertriglyceridemia in Miniature Schnauzers would lead to normalization of serum 
liver enzyme activities. Clinicians should be aware of the potential that 
hypertriglyceridemia in Miniature Schnauzers, especially when serum triglyceride 
concentrations are > 400 mg/dL, can be associated with high serum liver enzyme 
activities. Whether these patients require additional diagnostic testing to identify liver 
disorders remains to be determined. In human beings, isolated increases in ALT 
activity are generally considered to be benign, but have also been associated with 
cirrhosis in 10% to 17% of cases and have been identified in an even higher 
proportion of patients with clinically important fibrosis.
16
 Anecdotal observations 
suggest that some Miniature Schnauzers with hypertriglyceridemia might develop 
hepatic insufficiency secondary to severe vacuolar hepatopathy.
21
 Also, gallbladder 
mucoceles, which might be associated with hypertriglyceridemia, can often lead to 
death or euthanasia.
24
 Given the fact that most dogs in the present study had activities 
for > 1 liver enzyme that would be considered clinically important (ie, > 2 times the 
upper reference limit), additional diagnostic testing would seem appropriate.. 
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2.7.    Footnotes
 
a. Roche/Hitachi Modular Analytics D2400 module, Roche Diagnostics, 
Indianapolis, Ind. 
b. Roche/Hitachi Modular Analytics P800 module, Roche Diagnostics, 
Indianapolis, Ind.  
c. Prism5, GraphPad, San Diego, Calif.
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IV    Discussion 
Idiopathic hypertriglyceridemia is considered to be a relatively common disorder in 
Miniature Schnauzers in the United States (ROGERS et al., 1975a; FORD, 1993; 
WHITNEY et al., 1993; FORD, 1996). However, the true prevalence of this disorder 
in Miniature Schnauzers remains unknown, because the studies that have been 
conducted so far are limited to small case series (WHITNEY et al., 1993). In addition, 
studies investigating the clinical implications of idiopathic hypertriglyceridemia in 
large populations of Miniature Schnauzers, as well as the effect of age, sex, and 
reproductive status, on serum triglyceride concentrations are lacking.  
 
In the first part of the present study, determination of the prevalence of 
hypertriglyceridemia in a relatively large population of healthy Miniature Schnauzers, 
as well as further characterization of this condition, was attempted. Based on the 
results of this part of the study, it can be concluded that hypertriglyceridemia is 
common in healthy Miniature Schnauzers in the United States. Overall, about one-
third of the enrolled Miniature Schnauzers had serum triglyceride concentrations 
above the upper limit of the reference range. However, the percentage of Miniature 
Schnauzers with hypertriglyceridemia was much greater in older dogs, with 75% of 
Miniature Schnauzers ≥ 9 years old being affected.  
 
Miniature Schnauzers enrolled in this study came from many different locations 
within the United States, thus minimizing the possibility of selection of populations 
that were more inbred than the general Miniature Schnauzer population. Thus, 
findings of this study are believed to reflect the general population of Miniature 
Schnauzers in the United States. 
 
Most of the affected Miniature Schnauzers had mildly increased serum triglyceride 
concentrations, but a considerable percentage (11.5%) had moderately to severely 
increased serum triglyceride concentrations. As mentioned earlier, dogs with severe 
hypertriglyceridemia might be at an increased risk for the development of 
complications such as pancreatitis and/or seizures (BODKIN, 1992; BAUER, 1995; 
FORD, 1996; BAUER, 2004; WILLIAMS & STEINER, 2005). In addition, because 
hypertriglyceridemia is a common feature of other (mostly endocrine) diseases, the 
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findings of this study are important for veterinarians who may be evaluating 
Miniature Schnauzers with hyperlipidemia. A large proportion of healthy Miniature 
Schnauzers in the United States are expected to have mild, moderate, or even severe 
increases in serum triglyceride concentrations, and further investigation of the 
etiology of hypertriglyceridemia in Miniature Schnauzers may not be indicated in the 
absence of clinical or clinicopathological findings. 
 
The development of diseases that cause secondary hypertriglyceridemia (e.g., diabetes 
mellitus) in Miniature Schnauzers that also have primary hypertriglyceridemia, would 
be expected to potentially lead to additional increases in serum triglyceride 
concentrations. This means that, if the severity of hypertriglyceridemia correlates with 
the potential for developing complications secondary to hypertriglyceridemia, 
Miniature Schnauzers with both primary and secondary hypertriglyceridemia might 
be at higher risk for developing complications. 
 
In the Miniature Schnauzers enrolled in the present study, serum 
hypercholesterolemia was noted almost exclusively in association with moderate to 
severe hypertriglyceridemia. None of the Miniature Schnauzers with normal serum 
triglyceride concentrations had hypercholesterolemia. Also, many Miniature 
Schnauzers with hypertriglyceridemia had normal serum cholesterol concentrations. 
These findings indicate that hypercholesterolemia is variably present in Miniature 
Schnauzers with hypertriglyceridemia. Hypercholesterolemia may be a secondary 
feature that accompanies moderate to severe hypertriglyceridemia in Miniature 
Schnauzers, resulting from decreased clearance, increased production, or both, of 
chylomicrons and VLDL, as these 2 lipoprotein molecules also contain small amounts 
of free and esterified cholesterol (RIFAI et al, 1999). 
 
Both the percentages of Miniature Schnauzers with hypertriglyceridemia and the 
degree of hypertriglyceridemia increased with age. More than 75% of Miniature 
Schnauzers ≥ 9 years of age in this study had increased serum triglyceride 
concentrations, and the vast majority (>80%) of Miniature Schnauzers with moderate 
to severe hypertriglyceridemia were 6 years or older. This observation suggests that 
later development of hypertriglyceridemia cannot be excluded in young Miniature 
Schnauzer dogs found to have normal serum triglyceride concentrations. A genetic 
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marker may help identify affected dogs before the development of 
hypertriglyceridemia. However, some young Miniature Schnauzers may present with 
hypertriglyceridemia. 
 
In human beings, the presence of hypertriglyceridemia has been associated with the 
development of fatty liver, increased serum liver enzyme activities, and a condition 
known as nonalcoholic fatty liver disease (NAFLD) (ASSY et al., 2000; ANGULO, 
2002; DE BRUIN et al., 2004; BROUWERS et al., 2007). Studies investigating a 
possible association between hypertriglyceridemia, increased serum liver enzyme 
activities, and liver disease have not been described in dogs. Thus, the aim of the 
second part of the study presented here was to investigate serum liver enzyme 
activities in Miniature Schnauzers with hypertriglyceridemia and to compare them 
with those of Miniature Schnauzers with normal serum triglyceride concentrations. 
 
Results of this second part of the study showed that moderate to severe 
hypertriglyceridemia (>400 mg/dL) was significantly associated with increased serum 
liver enzyme activities in Miniature Schnauzers. Although significant associations 
between moderate to severe hypertriglyceridemia and high serum liver enzyme 
activities were found for all enzymes tested, the most profound associations involved 
serum ALP activity (Miniature Schnauzers with moderate to severe 
hypertriglyceridemia were 192.6 times more likely to have an increased serum ALP 
activity). In addition, there was a strong association between hypertriglyceridemia and 
concurrent elevation of two or more serum liver enzyme activities (Miniature 
Schnauzers with moderate to severe hypertriglyceridemia were 31 times more likely 
to have elevations of two or more serum liver enzyme activities).  
 
The etiology of elevated serum liver enzyme activities in hypertriglyceridemic 
Miniature Schnauzers cannot be determined based on the results of the present study. 
In human beings, hypertriglyceridemia has been associated with fatty infiltration of 
the liver leading to asymptomatic increases in serum liver enzyme activities (ASSY et 
al., 2000; ANGULO, 2002; CLARK et al., 2003; KICHIAN et al., 2003; DE BRUIN 
et al., 2004; IOANNOU et al., 2006; PANTSARI & HARRISON, 2006; 
BROUWERS et al., 2007). In these cases, increases in serum liver enzyme activities 
are usually mild and involve different combinations of increases in ALT, AST, ALP, 
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and GGT (CLARK et al., 2003; IOANNOU et al., 2006; PANTSARI & HARRISON, 
2006). Although increases in serum ALT activity are more commonly reported in 
human patients with fatty liver or NAFLD, increases in ALP activity are also very 
common, and a recent study in humans showed that a subset of patients with 
histopathologically confirmed NAFLD present with isolated elevated serum ALP 
activities (CLARK et al., 2003). It is not known whether the increased serum liver 
enzyme activities identified in hypertriglyceridemic Miniature Schnauzers in the 
present study are associated with fatty infiltration of the liver, but this is quite likely. 
In the present study, high serum ALP, but not ALT (as is the case in humans) activity, 
showed the most common and strongest association with hypertriglyceridemia. This 
might indicate that the possible underlying hepatic change in hypertriglyceridemic 
Miniature Schnauzers differs from NAFLD in humans.  
 
ALP is a membrane-bound enzyme and its activity increases in serum as a result of 
increased enzyme synthesis stimulated by impaired bile flow and/or drug induction 
(CENTER, 1996a). Fatty infiltration of the liver can potentially lead to cholestasis and 
increases in serum ALP, and, to a lesser degree, GGT activities (CENTER, 1996a). In 
contrast, ALT and AST are cytosolic enzymes that leak from hepatocytes following 
injury and altered permeability of the hepatocellular membrane (CENTER, 1996a). 
Hepatocellular injury following fatty infiltration and inflammation of the liver might 
explain increases of these enzymes in hypertriglyceridemic Miniature Schnauzers. 
 
Anecdotal observations suggest that two conditions of the liver might be associated 
with hypertriglyceridemia in Miniature Schnauzers: vacuolar hepatopathy and 
gallbladder mucocele (CENTER, 1996b; SCHERK & CENTER, 2005). Vacuolar 
hepatopathy shares some common characteristics with some forms of NAFLD, such 
as the fact that both can be asymptomatic for long periods, and that 
histopathologically they are characterized by vacuole formation of hepatocytes 
(CENTER, 1996b; ANGULO, 2002; SCHERK & CENTER, 2005; HUBSCHER, 
2006). Gallbladder mucocele has been commonly reported in dog breeds that are 
predisposed to idiopathic hyperlipidemia (e.g., Miniature Schnauzers and Shetland 
Sheepdogs) and has also been described in humans with hyperlipidemia (BOLAND et 
al., 2002; AGUIRRE et al., 2007). A clear association between the presence of 
hyperlipidemia and a gallbladder mucocele formation has not been described in dogs. 
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However, in a recent study, an association between gallbladder mucocele formation 
and dyslipidemias (i.e., hypertriglyceridemia and hypercholesterolemia) was 
described in Shetland Sheepdogs (AGUIRRE et al., 2007). In this study, many of the 
dogs with gallbladder mucocele were found to have no clinical signs or biochemical 
abnormalities, except for an increased serum ALP activity in some cases (AGUIRRE 
et al., 2007). Whether this is one or the only cause of high serum liver enzyme 
activities in Miniature Schnauzers with hypertriglyceridemia remains to be 
determined. Further studies involving histopathologic and ultrasonographic 
examination of the liver are underway in order to confirm and further characterize 
potential concurrent liver disease in Miniature Schnauzers with hypertriglyceridemia. 
 
It is unknown how long hypertriglyceridemia must be present in order to lead to 
increases in serum liver enzyme activities. Also, it is unknown whether increases of 
serum liver enzyme activities are persistent or whether correction of 
hypertriglyceridemia in Miniature Schnauzers would lead to normalization of serum 
liver enzyme activities. Clinicians should be aware of the potential that 
hypertriglyceridemia in Miniature Schnauzers (especially when serum triglyceride 
concentrations are above 400 mg/dL) can be associated with increased serum liver 
enzyme activities. Whether or not these patients require any additional diagnostic 
work-up towards the diagnosis of hepatic disorders is unknown. In human beings, 
isolated aminotransferase elevations are generally considered to be benign, but have 
also been associated with cirrhosis in 10-17% of the cases and, in an even higher 
proportion of patients, with significant fibrosis (CLARK et al., 2003; ADAMS et al., 
2005; EKSTEDT et al., 2006). Anecdotal observations suggest that some Miniature 
Schnauzers with hypertriglyceridemia might develop hepatic insufficiency due to 
severe vacuolar hepatopathy (CENTER, 1996b). Also, gallbladder mucoceles which 
might be associated with hypertriglyceridemia can often lead to death or euthanasia of 
the animal (AGUIRRE et al., 2007). Given the fact that in the present study most dogs 
had serum elevations of more than one liver enzyme activity that were considered 
significant (i.e., > 2 times the upper limit of the reference range), additional diagnostic 
work-up for patients with hyperlipidemia and increased serum hepatic enzyme 
activities would seem appropriate. Retesting serum liver enzyme activities could be an 
alternative approach. 
 
Discussion 
 82 
Because idiopathic hypertriglyceridemia appears to be common in Miniature 
Schnauzers in the United States, and because Miniature Schnauzers with 
hypertriglyceridemia might be at increased risk for the development of secondary 
diseases (e.g., liver disease, pancreatitis, neurologic disease), determination of the 
etiology of hypertriglyceridemia is highly desirable in this breed as it could facilitate 
the prevention and management of this condition. In human beings, hereditary causes 
of hypertriglyceridemia are well documented (HEGELE, 2001; YUAN et al., 2007). 
Familial hypertriglyceridemia (transmitted as an autosomal dominant disorder of 
unknown etiology), lipoprotein lipase deficiency (transmitted as an autosomal 
recessive disorder), and familial apolipoprotein C-II deficiency (transmitted as an 
autosomal recessive disorder) are disorders with a genetic basis that all lead to 
increases in serum triglyceride concentrations due to increased concentrations of 
VLDL, chylomicrons, or both (HEGELE, 2001; YUAN et al., 2007). The cause of 
idiopathic hypertriglyceridemia in Miniature Schnauzers has not yet been identified, 
but an underlying genetic defect is suspected. A recent study in Miniature Schnauzers 
with hypertriglyceridemia and pancreatitis failed to identify any mutations of the 
lipoprotein lipase gene, suggesting that inherited lipoprotein lipase dysfunction is not 
the cause of hypertriglyceridemia in this breed (SCHICKEL, 2005a, SCHICKEL et al, 
2005b). In another recent study, the gene encoding the apolipoprotein C-II was 
sequenced in Miniature Schnauzers with idiopathic hypertriglyceridemia, Miniature 
Schnauzers with normal serum triglyceride concentrations, and dogs of other breeds 
(XENOULIS, 2008). However, no mutations that co-segregated with 
hypertriglyceridemia were identified (XENOULIS, 2008). Further studies are needed 
and are underway in order to determine the underlying genetic defect responsible for 
hypertriglyceridemia in Miniature Schnauzers.  
 
In conclusion, idiopathic hypertriglyceridemia is common in healthy Miniature 
Schnauzers in the United States. There is no difference between male and female 
Miniature Schnauzers with regards to the prevalence of hypertriglyceridemia. Both 
the prevalence and severity of hypertriglyceridemia increase with age in Miniature 
Schnauzers. Due to the high prevalence of idiopathic hypertriglyceridemia in 
Miniature Schnauzers, extensive diagnostic testing aiming in identifying the cause of 
hypertriglyceridemia may not be necessary in otherwise healthy Miniature 
Schnauzers. All Miniature Schnauzers in the United States should potentially be 
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evaluated for hypertriglyceridemia while they are healthy, because this information 
may be useful for avoidance of misinterpretation of increased serum triglyceride 
concentrations when the dogs become sick. In addition, veterinarians might consider 
offering low fat diets to hypertriglyceridemic dogs in order to avoid possible 
complications of hypertriglyceridemia. Due to the fact that hypercholesterolemia was 
found only in association with hypertriglyceridemia, the presence of 
hypercholesterolemia alone in Miniature Schnauzers might require additional 
diagnostic investigation. Clinicians should be aware of the potential that 
hypertriglyceridemia in Miniature Schnauzers, especially when serum triglyceride 
concentrations are > 400 mg/dL, can be associated with increased serum hepatic 
enzyme activities. Possible causes of increased serum liver enzyme activities in 
hypertriglyceridemic Miniature Schnauzers include fatty infiltration of the liver 
and/or gallbladder mucocele formation. Additional diagnostic work-up or retesting of 
serum liver enzyme activities should be recommended in hypertriglyceridemic 
Miniature Schnauzers with high serum liver enzyme activities. 
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V    Summary 
Idiopathic hypertriglyceridemia has been reported in Miniature Schnauzers. However, 
studies investigating the prevalence of this disorder in a large population of Miniature 
Schnauzers are lacking. 192 healthy Miniature Schnauzers and 38 healthy dogs of 
other breeds (control dogs) were enrolled in this study. Serum triglyceride and 
cholesterol concentrations were measured and statistically compared between the 
Miniature Schnauzers and the control group. Dogs were categorized based on their 
age, and median serum triglyceride concentrations were compared among different 
age groups. A total of 63 (32.8%) of the 192 Miniature Schnauzers had serum 
triglyceride concentrations above the upper limit of the reference range. In contrast, of 
the 38 control dogs, only 2 (5.3%) had serum triglyceride concentrations above the 
upper limit of the reference range. The median serum triglyceride concentration in 
Miniature Schnauzers was 73.5 mg/dL, which was significantly higher compared to 
that of the control group (median: 55 mg/dL; p=0.0005). Serum cholesterol 
concentration was above the upper limit of the reference range in 9 (9.0%) of 100 
Miniature Schnauzers and in 2 (5.3%) of the control dogs. Mean serum cholesterol 
concentrations were not significantly different between the 2 groups (p=0.1374). 
Median serum triglyceride concentrations in Miniature Schnauzers increased 
significantly with age (p<0.0001), and there was a significant positive correlation 
between serum triglyceride concentration and age (Spearman r=0.47; p<0.0001). 
There was no difference in serum triglyceride concentrations between male and 
female Miniature Schnauzers (p=0.48). Healthy Miniature Schnauzers had a high 
prevalence of hypertriglyceridemia compared to healthy dogs of other breeds. Both 
the prevalence and severity of hypertriglyceridemia increased with age. 
To determine whether hypertriglyceridemia in healthy Miniature Schnauzers was 
associated with increased serum liver enzyme activities, 65 Miniature Schnauzers 
with normal serum triglyceride concentrations (group 1), 20 Miniature Schnauzers 
with slightly increased serum triglyceride concentrations (group 2), and 20 Miniature 
Schnauzers with moderately to severely increased serum triglyceride concentrations 
(group 3) were evaluated. Questionnaires regarding each dog’s medical history were 
collected, and serum alkaline phosphatase (ALP), alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), and γ-glutamyltransferase (GGT) activities were 
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measured. Median serum ALP activity was significantly higher in group 3 than in 
group 1 or 2, but was not significantly higher in group 2 than in group 1. Median 
serum ALT activity was significantly higher in group 3 than in group 1, but was not 
significantly different between any of the other groups. Compared with group 1, 
group 2 and 3 were significantly more likely to have an increased serum ALP activity 
(odds ratio, 26.2 and 192.6, respectively). Group 3 was also significantly more likely 
to have an increased serum ALT activity (odds ratio, 8.0), serum AST activity (odds 
ratio, 3.7), or serum GGT activity (odds ratio, 11.3), than group 1. Group 3 was 
significantly more likely (odds ratio, 31.0) to have ≥ 2 high serum liver enzyme 
activities than was group 1. Results suggested that moderate to severe 
hypertriglyceridemia was associated with high serum liver enzyme activities in 
Miniature Schnauzers. 
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VI    Zusammenfassung 
Die idiopathische Hypertriglyzeridämie des Zwergschnauzers wurde bereits zuvor in 
der Literatur beschrieben. Es fehlen jedoch Studien, welche die Prävalenz der 
Hypertriglyzeridämie in einer größeren Gruppe von Hunden dieser Rasse 
untersuchen. Die folgende Studie umfasste 192 klinisch gesunde Zwergschnauzer und 
38 klinisch gesunde Hunde anderer Rassen (Kontrollgruppe). Die Triglyzerid- und 
Cholesterolkonzentrationen im Serum wurden in beiden Gruppen gemessen und 
statistisch ausgewertet. Hunde wurden in verschiedene Altersgruppen eingeteilt und 
die Triglyzeridkonzentration im Serum wurde zwischen den einzelnen Gruppen 
verglichen. Insgesamt wiesen 63 (32,8 %) der 192 Zwergschnauzer 
Triglyzeridkonzentrationen im Serum außerhalb des Referenzbereichs auf. Dagegen 
hatten von den insgesamt 38 Hunden der Kontrollgruppe nur 2 (5,3 %) Hunde 
Triglyzeridkonzentrationen im Serum außerhalb des Referenzbereichs. Der 
Medianwert der Triglyzeridkonzentration im Serum betrug bei Zwergschnauzern 73,5 
mg/dL, und war damit signifikant höher als der Medianwert der Kontrollgruppe 
(Medianwert: 55 mg/dL; p=0,0005). Die Cholesterolkonzentration im Serum lag bei 9 
(9,0 %) der 100 Zwergschnauzer und bei 2 Hunden (5,3 %) der Kontrollgruppe über 
dem Referenzbereiches. Der Mittelwert der Cholesterolkonzentration im Serum war 
nicht signifikant unterschiedlich zwischen beiden Gruppen (p=0,1374). Der 
Medianwert der Triglyzeridkonzentration im Serum der Zwergschnauzer war bei 
älteren Hunden signifikant höher (p<0,0001), und eine positive Korrelation wurde 
zwischen der Triglyzeridkonzentration im Serum und dem Alter der Tiere beobachtet 
(Spearman r=0,47; p<0,0001). Die Triglyzeridkonzentration im Serum war zwischen 
weiblichen und männlichen Tieren nicht signifikant verschieden (p=0,48). Die 
Ergebnisse dieser Studie ließen darauf schließen, dass klinisch gesunde 
Zwergschnauzer eine höhere Prävalenz von Hypertriglyzeridämie im Vergleich zu 
klinisch gesunden Hunden anderer Rassen aufweisen, und dass die Prävalenz sowie 
der Grad dieser Abnormalität mit steigendem Alter zunehmen. 
Der zweite Teil dieser Arbeit untersuchte die Frage, ob Hypertriglyzeridämie 
möglicherweise mit erhöhten Leberenzymwerten assoziiert ist. Diese Studie umfasste 
65 Zwergschnauzer mit physiologischer Triglyzeridkonzentration im Serum (Gruppe 
1), 20 Zwergschnauzer mit leicht erhöhter Triglyzeridkonzentration im Serum 
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(Gruppe 2), and 20 Zwergschnauzer mit mittelgradig bis hochgradig erhöhter 
Triglyzeridkonzentration im Serum (Gruppe 3). Fragebögen bezüglich des 
Gesundheitszustandes der Hunde wurden ausgewertet, und die Serumaktivität der 
folgenden Leberenzyme wurde gemessen: Alkalische Phosphatase (ALP), 
Alaninaminotransferase (ALT), Aspartataminotransferase (AST), und γ-
Glutamyltransferase (GGT). Die Hunde der Gruppe 3 hatten einen signifikant höheren 
Medianwert der ALP-Serumaktivität verglichen mit Hunden der Gruppen 1 und 2. 
Zwischen den Gruppen 1 und 2 gab es allerdings keinen signifikanten Unterschied 
bezüglich der Höhe der ALP-Serumaktivität. Die Hunde der Gruppe 3 hatten einen 
signifikant höheren Medianwert der ALT-Serumaktivität verglichen mit Gruppe 1. Im 
Vergleich zur Gruppe 1 hatten die Hunde der Gruppe 2 und 3 ein größeres Risiko für 
eine erhöhte ALP-Serumaktivität (odds ratio 26,2 bzw. 192,6). Zusätzlich hatten die 
Hunde der Gruppe 3 im Vergleich zu Gruppe 1 ein  größeres Risiko für eine erhöhte 
Serumaktivität der ALT (odds ratio 8,0), AST (odds ratio 3,7) und GGT (odds ratio 
11,3). Im Vergleich zu Gruppe 1 hatten Hunde der Gruppe 3 weiterhin ein  größeres 
Risiko (odd ratio 31,0) für eine Erhöhung von mindestens zwei der untersuchten 
Leberenzymaktivitäten. Die Ergebnisse dieser Studie deuteten darauf hin, dass 
mittelgradig bis hochgradig erhöhte Triglyzeridkonzentrationen im Serum bei 
Zwergschnauzern oft mit einer erhöhten Serumaktivität der Leberenzyme assoziiert 
sind. 
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